

## Supplementary materials

### Genetic architecture of lumbar spinal stenosis

Ville Salo<sup>1,2</sup>, Juhani Määttä<sup>1,3</sup>, Jasmin Takala<sup>2,3</sup>, Anni Heikkilä<sup>2,3</sup>, FinnGen<sup>5</sup>, Ene Reimann<sup>6</sup>, Reedik Mägi<sup>6</sup>, Estonian Biobank Research Team<sup>6,7</sup>, Kadri Reis<sup>6</sup>, Abdelrahman G.Elhanas<sup>6</sup>, Anu Reigo<sup>6</sup>, Priit Palta<sup>6,8</sup>, Tõnu Esko<sup>6</sup>, Ville Leinonen<sup>9</sup>, Jaro Karppinen<sup>1,3,10</sup>, Eeva Sliz<sup>2,3\*</sup>, Johannes Kettunen<sup>2,3\*</sup>

<sup>1</sup> Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

<sup>2</sup> Biocenter Oulu, Oulu, Finland

<sup>3</sup> Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

<sup>4</sup> Research unit of Population Health, Faculty of Medicine, and Biocenter Oulu, University of Oulu, Oulu, Finland

<sup>5</sup> A list of FinnGen authors and their affiliations available in the supplements

<sup>6</sup> Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

<sup>7</sup> A list of Estonian Biobank Research Team authors and their affiliations available in the supplements

<sup>8</sup> Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki

<sup>9</sup> Neurosurgery, Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland and Department of Neurosurgery, Kuopio University Hospital, Kuopio, Finland

<sup>10</sup> Rehabilitation Services of Wellbeing Services County of South Karelia, Lappeenranta, Finland

\* These authors contributed equally to this work

**Supplementary Note.** FinnGen DF9 Ethics statement

**Fig. S1** Lead variant effect estimates in every dataset

**Fig. S2** Lead variant effect estimates in meta-analysis and sensitivity analysis

**Fig. S3** MAGMA tissue expression analysis results

**Fig. S4** Kaplan Meier plots for potential early-onset variants

**Fig. S5.1** Scatterplot for whole body fat-free mass that could potentially be causal for LSS

**Fig. S5.2** Scatterplot for body mass index (BMI) that could potentially be causal for LSS

**Fig. S5.3** Scatterplot for hip circumference that could potentially be causal for LSS

**Fig. S5.4** Scatterplot for whole body fat mass that could potentially be causal for LSS

**Fig. S6** Scatterplot for back pain for which LSS is potentially causal

**Fig. S7.1** Leave-one-out: Whole body fat-free mass -> LSS

**Fig. S7.2** Leave-one-out: Body mass index (BMI) -> LSS

**Fig. S7.3** Leave-one-out: Hip circumference -> LSS

**Fig. S7.4** Leave-one-out: Whole body fat mass -> LSS

**Fig. S8** Leave-one-out: LSS -> Back pain

**Table S1** Study populations and phenotype characterization

**Table S2** The lead variants at the 56 LSS-associated loci observed in the meta-analysis

**Table S3** Structural information about lead variants and potential candidate genes

**Table S4** Cohort level odds ratios and effect allele frequencies

**Table S5** Effect estimate differences between meta-analysis and surgical GWAS

**Table S6** FastBAT results

**Table S7** eQTL colocalization results

**Table S8** Cumulative morbidities and age differences between lead variant homozygotes

**Table S9** Genetic correlations between LSS and 517 other traits

**Table S10** Mendelian randomization results

**Table S11** Bi-directional Mendelian randomization risk factors


## References

### **Supplementary Note.** FinnGen R9 Ethics statement


Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/202, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4<sup>th</sup> July 2019.


The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 9 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7, BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), AB20-5926 and amendment #1 (April 23 2020) and it's modification (Sep 22 2021), Biobank Borealis of Northern Finland\_2017\_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25<sup>th</sup> Aug 2020.




**Fig. S1.** The forest plot displays the effect estimates and 95% confidence intervals for LSS-associated lead variants in the meta-analysis [green], as well as each dataset separately (FinnGen [orange], Estonian Biobank [red], and UK Biobank [blue]). Candidate gene, rsid and effect allele were used as variant identifiers. Table S4 displays the cohort level odds ratios and effect allele frequencies.




**Fig. S2.** A comparison of the effect sizes of the lead variants discovered in the original meta-analysis (Meta-analysis, ICD-10:M48.0 [green]) and in sensitivity analysis with LSS patients requiring surgery (Surgical GWAS, Nomesco v1.15: ABC36, ABC56, ABC66, ABC99, NAG61, NAG62, NAG63, NAG66, NAG67, and NAG99 [red]). Between meta-analysis and surgical GWAS we observed statistically significant effect differences for *NGF*, *RAB28*, *BMP6*, *TRIM38*, *AGMO*, *TNFSF11* and *ALDH1A2* variants (Fig. 1B). Results of the effect differences and p-values for difference can also be seen from Table S5.




**Fig S3.** MAGMA tissue expression analysis<sup>1</sup> results, no genome-wide significant results were observed in tissue expression analysis. y-axis, -log 10 P-value; x-axis, tissues (GTEx Output-General tissues). Analysis was performed by using FUMA<sup>2</sup>.




**Fig. S4** Kaplan-Meier plots for variants located near the *OTUD7B*, *USP37*, *CDC5L*, *SOX5* and *SMAD3* genes. For these variants, we observed that the cumulative incidence of LSS differed between homozygotes already at the age of 40. The graphs on the left are based on FinnGen results, while those on the right are based on Estonian Biobank replication. Age in years is on the x-axis, and the corresponding fraction of the cases is on the y-axis. The grey line depicts homozygotes for the effect allele, the orange homozygotes for the other allele, and the blue line corresponds to heterozygotes having one copy of each allele. The heterozygote differences were not tested and are just shown for illustration.




**Fig. S5.1** Scatterplot for whole body fat-free mass that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Whole body fat-free mass || id:ukb-b-13354” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of  $r^2=0.001$  and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




**Fig. S5.2** Scatterplot for body mass index (BMI) that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Body mass index (BMI) || id:ukb-b-19953” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of  $r^2=0.001$  and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




**Fig. S5.3** Scatterplot for hip circumference that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Hip circumference || id:ukb-b-15590” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of  $r^2=0.001$  and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




**Fig. S5.4** Scatterplot for whole body fat mass that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Whole body fat mass || id:ukb-b-19393” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of  $r^2=0.001$  and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




**Fig. S6** Scatterplot for back pain for which LSS is potentially causal. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Pain type(s) experienced in last month: Back pain || id:ukb-b-9838” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of  $r^2=0.001$  and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




**Fig. S7.1** Leave-one-out: Whole body fat-free mass -> LSS




**Fig. S7.2** Leave-one-out: Body mass index (BMI) -> LSS



**Fig. S7.3** Leave-one-out: Hip circumference -> LSS



**Fig. S7.4** Leave-one-out: Whole body fat mass -> LSS



**Fig. S8.1** Leave-one-out: LSS -> Back pain

**Table S1** Case and controls in all study populations and phenotype characterization.

<b>Study population</b>	<b>Cases</b>	<b>Controls</b>	<b>Sample prevalence</b>	<b>Total</b>
FinnGen	18 989	270 964	6.5%	289 953
Estonian Biobank	6146	66 533	8.4%	73 279
UK Biobank	5134	401 917	1.3%	407 051
<b>Meta-analysis</b>	<b>30 269</b>	<b>739 414</b>	<b>3.9%</b>	<b>769 683</b>
Sensitivity analysis (FinnGen)				
Surgical GWAS	8627	270 773	3.1%	279 400

<b>Study</b>	<b>Revision / Codes</b>	<b>Codes</b>
<b>Meta-analysis</b>		
EstBB	ICD-10	M48.0
UKBB	ICD-10	M48.0
FinnGen	ICD-10	M48.0
	ICD-9	7230A, 7240A, 7240B
FinnGen control exclusions	ICD-10	M40 (M40.0, M40.1, M40.2, M40.3, M40.4, M40.5), M41 (M41.0, M41.1, M41.2, M41.3, M41.4, M41.5, M41.6, M41.8, M41.9), M42 (M42.0, M42.1, M42.9), M43 (M43.0, M43.1, M43.2, M43.3, M43.4, M43.5, M43.6, M43.8, M43.9), M45, M46 (M46.0, M46.1, M46.2, M46.3, M46.4, M46.5, M46.8, M46.9), M47 (M47.0, M47.1, M47.2, M47.8, M47.9), M48.1, M48.2, M48.3, M48.4, M48.5, M48.8, M48.9, M49 (M49.0, M49.1, M49.2, M49.3, M49.4, M49.5, M49.8), M50 (M50.0, M50.1, M50.2, M50.3, M50.8, M50.9), M51 (M51.1, M51.9), M53 (M53.0, M53.1, M53.2, M53.3, M53.8, M53.9), M54 (M54.0, M54.1, M54.2, M54.3, M54.4, M54.5, M54.6, M54.8, M54.9), M76 (M76.0, M76.1, M76.2, M76.3, M76.4, M76.5, M76.6, M76.7, M76.8, M76.9)
	ICD-9	737.0A, 727.1A, 737.2A, 738.4A, 723.5A, 732.8A, 732.8B, 732.8X, 732.9X, 737.9X, 720.0A, 720.2A, 720.8A, 720.9X, 721.0A, 721.1A, 721.2A, 721.3A, 721.4A, 724.0B, 721.6A, 722.7A, 722.7C, 722.4A, 722.0A, 722.7B, 722.4B, 722.8A, 723.2A, 723.3A, 724.6A, 724.8X, 724.9X, 724.4A, 723.4A, 723.1A, 724.2A, 724.1A, 724.5A, 726.5B, 726.6G, 726.6C, 726.6B, 726.6D, 726.7A, 726.6B, 726.6X, 726.7B, 726.7X, 722.1A, 722.1C, 722.3A, 722.5A, 722.5B, 722.6X, 722.8C, 722.9X
	ICD-8	71720, 73599, 73500, 71240, 71310, 71311, 71312, 71319, 72699, 71320, 72500, 72501, 72509, 72810, 72820, 72828, 78880, 78830, 78888, 72899, 72898, 72890, 72870, 71700, 72850, 72800, 72898, 72899, 72510, 72519, 72520, 72551, 72559, 72588, 72599
<b>Sensitivity analysis (FinnGen)</b>		
<b>Surgical GWAS</b>		
Step 1) Characterization of LSS patients		
	ICD-10	M48.0
	ICD-9	7230A, 7240A, 7240B
Step 2) Patients who have undergone surgery were selected from the characterized LSS patient group.	NOMESCO, version 1.15	ABC36, ABC56, ABC66, ABC99, NAG61, NAG62, NAG63, NAG66, NAG67, NAG99
Step 3) LSS cases that had not had surgery were omitted from the analysis. Patients who had undergone surgery but had not been diagnosed with LSS were also excluded. Otherwise, the control group was chosen in a similar manner as in the meta-analysis.		

**Table S2.** The lead variants at 54 LSS-associated ( $p < 5 \times 10^{-8}$ ) loci in the meta-analysis. The meta-analysis consisted total of 30 269 cases and 739 414 controls from FinnGen, the Estonian Biobank, and the UK Biobank. Secondary signals were observed from four loci and conditional variants have been marked with \*-symbol.

Locus	Candidate gene	CHR: POS	rsid	EA	OA	OR (95% CI)	p-value	EAF	Fin Enric.	Ref.
<b>Meta-analysis (FinnGen, EstBB, UKBB)</b>										
1p36.11	<i>RUNX3</i>	1:24894533	rs9438857	G	A	0.90 (0.88-0.92)	4.92e-08	0.31	0.86	Novel
1p13.2	<i>NGF</i>	1:115287365	rs6327	T	C	0.93 (0.91-0.95)	5.4e-16	0.47	1.06	Novel
"	<i>NGF*</i>	1:115170045	rs1286225	G	C	0.94 (0.92-0.96)	9.68e-11	0.68	1.01	
1q21.2	<i>OTUD7B</i>	1:149934520	rs11205303	C	T	0.92 (0.90-0.94)	1.76e-19	0.38	0.75	Novel
1q21.3	<i>ZNF687</i>	1:151032308	rs147042690	T	C	1.21 (1.14-1.27)	8.5e-09	0.01	34.27	Novel
1q32.1	<i>PTPRC</i>	1:198819354	rs72739729	C	G	0.91 (0.88-0.93)	2.18e-15	0.15	1.19	Novel
2p13.3	<i>GFPT1</i>	2:69341550	rs4340572	G	A	0.91 (0.89-0.93)	5.64e-25	0.57	0.95	
"	<i>GFPT1*</i>	2:70422594	rs17500661	A	G	0.95 (0.93-0.97)	1.23e-08	0.29	1.06	
2q35	<i>USP37</i>	2:218486683	rs60362609	G	C	0.94 (0.92-0.96)	1.47e-08	0.61	0.98	Novel
3p21.31	<i>DAG1</i>	3:49498696	rs138073019	TTTA	T	0.95 (0.93-0.97)	9.31e-09	0.35	1.48	Novel
4p15.33	<i>RAB28</i>	4:12893286	rs3057070	A	AGAG	0.92 (0.90-0.94)	3.22e-15	0.24	1.08	Novel
5p13.1	<i>DAB2</i>	5:39844572	rs148346348	ATATG	A	1.08 (1.05-1.10)	7.56e-10	0.17	1.29	Novel
5q11.2	<i>ITGA2</i>	5:53038840	rs11747379	A	C	1.08 (1.05-1.10)	9.21e-11	0.18	1.07	Novel
5q33.3	<i>EBF1</i>	5:159017122	rs200608668	G	GC	1.06 (1.04-1.09)	3.28e-08	0.22	0.66	Novel
6p24.3	<i>BMP6</i>	6:7797607	rs10498672	G	C	1.08 (1.06-1.11)	9.09e-14	0.20	1.24	Novel
6p22.2	<i>TRIM38</i>	6:26239176	rs9358913	G	A	0.94 (0.93-0.96)	8.72e-10	0.32	1.62	Novel
6p22.1	<i>HLA</i>	6:30106665	rs62390186	A	T	0.94 (0.92-0.96)	3.99e-08	0.18	1.83	Novel
6p21.33	<i>HLA</i>	6:31133806	rs4294047	A	G	0.91 (0.88-0.93)	2.93e-13	0.11	1.97	Novel
6p21.32	<i>HLA</i>	6:32634706	rs17205170	T	G	0.92 (0.90-0.94)	3.33e-13	0.20	1.34	Novel
6p21.1	<i>CDC5L</i>	6:44479182	rs770012	A	C	1.07 (1.05-1.08)	1.02e-12	0.53	0.99	Novel
6q21	<i>LIN28B</i>	6:105005542	rs314261	C	A	1.05 (1.03-1.07)	2.18e-08	0.57	1.03	Novel
6q22.1	<i>COL10A1</i>	6:116167743	rs7739896	G	A	0.95 (0.93-0.97)	4.57e-09	0.51	0.92	
6q23.2	<i>EY44</i>	6:132913577	rs2764217	A	G	1.06 (1.05-1.08)	1.36e-10	0.43	0.97	Novel
7p22.1	<i>FOXK1</i>	7:4638590	rs28658109	C	T	0.93 (0.91-0.96)	1.08e-08	0.19	1.35	Novel
7p21.2	<i>AGMO</i>	7:15344063	rs75674922	G	A	1.09 (1.06-1.11)	6.72e-12	0.13	1.83	
7p21.1	<i>TWIST1</i>	7:19488615	rs2390116	T	C	0.95 (0.93-0.97)	2.93e-08	0.49	0.97	Novel
7p15.1	<i>JAZF1</i>	7:28156794	rs849135	A	G	0.95 (0.93-0.97)	7.32e-09	0.49	0.90	Novel
7q11.22	<i>Empty</i>	7:69064281	rs139203647	G	GT	1.08 (1.05-1.11)	1.01e-08	0.15	1.22	Novel
7q21.3	<i>DYNCIII</i>	7:95941237	rs11769842	C	T	1.08 (1.06-1.10)	1.18e-11	0.75	1.06	
10p12.1	<i>MKX</i>	10:27612430	rs2637326	T	G	1.06 (1.05-1.08)	3.44e-12	0.47	0.73	Novel
11p14.1	<i>MPPED2</i>	11:30788512	rs607165	C	T	1.05 (1.04-1.07)	1.94e-09	0.44	1.19	Novel
12p12.2	<i>PDE3A</i>	12:20427791	rs73067286	A	T	0.93 (0.91-0.95)	2.1e-13	0.23	1.22	
"	<i>PDE3A*</i>	12:20215335	rs60691990	C	T	0.93 (0.91-0.95)	1.86e-11	0.29	0.65	
12p12.1	<i>SOX5</i>	12:23821470	rs12308843	C	G	1.08 (1.06-1.10)	3.3e-15	0.27	1.28	Novel
12p11.22	<i>CCDC91</i>	12:27844985	rs7958415	T	C	0.93 (0.91-0.95)	1.07e-13	0.35	0.72	Novel
"	<i>CCDC91*</i>	12:27958482	rs189814310	C	A	0.65 (0.51-0.80)	3.20e-09	0.005	3.97	
"	<i>CCDC91*</i>	12:28156247	rs2127315	T	A	0.94 (0.92-0.96)	1.45e-08	0.25	0.85	
"	<i>CCDC91*</i>	12:28933226	rs11049924	A	C	0.93 (0.91-0.96)	2.90e-08	0.15	0.92	
12q14.1	<i>GLI1</i>	12:57749071	rs2069506	A	C	0.94 (0.93-0.96)	1.56e-09	0.33	1.19	Novel
12q14.1	<i>USP15</i>	12:62218131	rs11174377	A	G	1.07 (1.05-1.10)	2.47e-09	0.17	0.97	Novel
12q24.31	<i>ZCCHC8</i>	12:122480161	rs10846978	C	T	1.06 (1.04-1.09)	4.49e-08	0.77	1.07	Novel
13q14.11	<i>TNFSF11</i>	13:42423131	rs9594751	T	C	0.95 (0.93-0.97)	3.09e-08	0.25	1.13	Novel
13q31.1	<i>SLTRK6</i>	13:8535178	rs9531779	G	C	0.94 (0.93-0.96)	9.15e-11	0.59	1.03	
14q11.2	<i>MMP14</i>	14:22843385	rs1042704	A	G	0.93 (0.91-0.96)	4.02e-10	0.22	1.00	Novel
14q32.33	<i>GPR132</i>	14:105137078	rs1022431	A	C	0.91 (0.88-0.95)	3.76e-08	0.09	0.78	Novel
15q21.3	<i>ALDH1A2</i>	15:58050948	rs4646570	C	G	1.06 (1.05-1.08)	5.47e-12	0.49	1.07	Novel
15q22.31	<i>PPIB</i>	15:64138226	rs148027154	A	T	1.28 (1.20-1.37)	3.52e-08	0.006	5.12	Novel
15q22.33	<i>SMAD3</i>	15:67072653	rs4776880	A	G	0.90 (0.88-0.92)	1.05e-28	0.35	1.10	
15q25.3	<i>PDE8A</i>	15:84986797	rs11629962	T	C	0.94 (0.92-0.96)	2.36e-08	0.25	1.14	Novel
16q23.2	<i>GAN</i>	16:81482778	rs2966084	G	A	0.94 (0.92-0.96)	4.3e-11	0.69	0.95	Novel
17q12	<i>SOCS7</i>	17:38474030	rs113353816	C	T	1.06 (1.04-1.09)	4.25e-08	0.83	0.90	Novel
17q24.1	<i>AXIN2</i>	17:65278900	rs16961974	C	T	1.06 (1.04-1.07)	2.75e-08	0.28	1.05	Novel
17q24.3	<i>Empty</i>	17:71476022	rs12941198	C	A	1.06 (1.04-1.08)	3.6e-08	0.78	1.02	Novel
18q21.2	<i>DCC</i>	18:53220821	rs6508210	C	A	1.08 (1.06-1.09)	2.64e-16	0.52	0.85	Novel
19p13.3	<i>CACTIN</i>	19:3537186	rs77733715	G	A	1.14 (1.09-1.18)	1.44e-08	0.03	5.24	Novel
19p13.11	<i>CRLF1</i>	19:18616479	rs2074177	G	A	0.93 (0.91-0.95)	1.03e-12	0.25	1.05	Novel
20p13	<i>DDRGK1</i>	20:2800795	rs11697820	T	C	0.95 (0.93-0.96)	5.15e-10	0.58	0.98	Novel
21q22.2	<i>ETS2</i>	21:39183865	rs111901809	T	TAGA GGGG CAGG GGGC G	1.05 (1.03-1.07)	3.94e-08	0.49	1.32	Novel
22q12.2	<i>OSM</i>	22:30026719	rs2285645	T	C	0.83 (0.78-0.89)	4.19e-12	0.02	14.95	Novel
Xq23	<i>CHRD1</i>	X:110450046	rs67648651	C	T	1.05 (1.04-1.07)	1.13e-11	0.40	0.87	Novel

Candidate gene, a gene at a new locus the biological function of which is likely to explain the LSS association; CHR: POS, chromosome and position (genome build hg38); rsid; SNP markers identification number; EA, effect allele; OA, other allele; OR, odds ratio; 95% CI, odds ratio 95% confidence interval; EAF, effect allele frequency; Fin Enric., enrichment in Finns (calculated FIN AF/NFEE AF in the Genome Aggregation Database [gnomAD, v.3.1.2], FIN AF is the allele frequency in Finns and NFEE AF is the allele frequency in Europeans (does not include Finns or Estonians)); REF, reference to literature reporting LSS association in the vicinity ( $\pm 1$ MB) of the lead variant. \*, for this variant p-value and OR have been adjusted for the effect of original lead variant at the locus through conditional analysis, the original lead variant is always above the conditional variant in the table

**Table S3** Structural information about the LSS-associated and Surgical LSS variants. Also, biological functions for novel potential candidate genes that we determined with the help of literature and databases (Genbank<sup>5</sup>, UniProt<sup>6</sup>, GTEx-Portal<sup>7</sup>). HLA region variants were excluded from the PheWAS.

Candidate gene	rsid	Variant type	PheWAS ↑	PheWAS ↓	A possible function related to LSS pathogenesis
<b>Meta-analysis (FinnGen, Estonian Biobank, UK Biobank)</b>					
<i>RUNX3</i>	rs9438857	Downstream gene variant	-	-	<i>RUNX3</i> lowers CD8+ T cell counts, so it has a role in the regulation of immune defence <sup>8</sup> .
<i>NGF</i>	rs6327	Intron	Adhesive capsulitis	Carpal tunnel syndrome, arthrosis, spondylosis, spondylolisthesis, hallux valgus	<i>NGF</i> stimulates axonal regeneration in the central nervous system as well as collateral sprouting of the peripheral sensory nerves. <i>NGF</i> production can lead to nociceptive nerve ingrowth in the spine, and it is also involved in neuronal apoptosis <sup>9,10</sup> .
<i>OTUD7B</i>	rs11205303	Missense	Angina pectoris, cardiac arrhythmias, major coronary heart disease event, coronary atherosclerosis, coronary revascularization	Hallux valgus, lumbar disc herniation, carpal tunnel syndrome	<i>OTUD7B</i> controls non-canonical NF-κB activation through deubiquitination <sup>11</sup> , its involvement in LSS pathogenesis has already been speculated in previous clinical studies concerning LSS <sup>12</sup> .
<i>ZNF687</i>	rs147042690	Intron	-	-	<i>ZNF687</i> has been linked to Paget disease in earlier studies <sup>13,14</sup> . There is evidence that <i>ZNF687</i> may influence bone development and differentiation <sup>15</sup> .
<i>PTPRC</i>	rs72739729	Intron	-	Low back pain, Spondylosis, lumbar disc herniation	Regulates T cell antigen receptor signaling <sup>16,17</sup> .
<i>GFPT1</i>	rs4340572	Intron	Dupuytren contracture	Lumbar disc herniation, spondylosis, spondylolisthesis, cervical disc disorders	-
<i>USP37</i>	rs60362609	Intron	-	-	The hedgehog pathway, which is regulated by <i>USP37</i> , has previously been connected to ligamentum flavum hypertrophy along with <i>GLI1</i> <sup>18-20</sup> .
<i>DAG1</i>	rs138073019	Intron	Ulcerative proctitis, inflammatory bowel disease, ulcerative colitis	Pain, spondylosis, shoulder lesions, lumbar disc herniation, hypertension, carpal tunnel syndrome	<i>DAG1</i> plays a role in neural development and has a known role in axon guidance <sup>21,22</sup> . It has also been linked to muscle dystrophies <sup>23</sup> .
<i>RAB28</i>	rs5856174	Intergenic	-	-	<i>RAB28</i> has been linked to kyphosis (curvature of the spine) in a previous study <sup>24</sup> , the genetic mechanism of action is potentially related to membrane trafficking or regulation of NF-κB nuclear transportation <sup>25,26</sup> .
<i>DAB2</i>	rs148346348	Intergenic	Spondylolisthesis	-	<i>DAB2</i> has multifaceted roles in signaling pathways involved in cellular differentiation, proliferation, migration, and it may contribute to immunological tolerance and suppression of inflammatory responses.

					In addition, it has been linked to TGF- $\beta$ signaling <sup>27,28</sup> .
<b>ITGA2</b>	rs11747379	Intron	Lumbar disc herniation, spondylolisthesis		A transmembrane receptor for collagens and other related proteins, the alpha subunit is encoded by <i>ITGA2</i> , also referred to as integrin $\alpha 2$ . <i>ITGA2</i> mediates the adhesion of various cell types to the extracellular matrix (ECM) by forming a heterodimer with an integrin beta subunit <sup>29</sup> .
<b>EBF1</b>	rs200608668	Intron	Obesity, hypertension	Varicose veins	<i>EBF1</i> regulates early B-cell differentiation by poising or activating lineage-specific genes and repressing genes associated with alternative cell fates <sup>30,31</sup> .
<b>BMP6</b>	rs10498672	Intron	Arthrosis, coxarthrosis		<i>BMP6</i> has an important role in bone and cartilage formation and repair <sup>32,33</sup> . It also potentially plays a role in inducing angiogenesis and neurogenesis <sup>34,35</sup> .
<b>TRIM38</b>	rs9358913	Upstream gene variant	Subacute thyroiditis	Hypothyroidism, atherosclerosis, hypertension, varicose veins, coeliac disease, arthrosis, gonarthrosis, autoimmune disease	<i>TRIM38</i> is an inflammatory modulator <sup>36</sup> . By suppressing NF- $\kappa$ B signalling, <i>TRIM38</i> can lessen apoptosis and degeneration of chondrocytes caused by IL-1 $\beta$ , it has been suggested that <i>TRIM38</i> may be involved in osteoarthritis <sup>37</sup> .
<b>HLA</b>	rs62390186	Intron	-	-	-
<b>HLA</b>	rs4294047	Intron	-	-	-
<b>HLA</b>	rs17205170	Intron	-	-	-
<b>CDC5L</b>	rs7770012	Intergenic	Bell's palsy, lumbar disc herniation, coxarthrosis, arthrosis	-	<i>CDC5L</i> has previously been associated with ossification of the posterior longitudinal ligament (OPLL) <sup>38,39</sup> . It has been discovered that <i>CDC5L</i> stimulates early chondrogenesis and cartilage growth and may contribute to the pathophysiology of OPLL by initiating the endochondral ossification process <sup>40</sup> .
<b>LIN28B</b>	rs314261	Intron	Carpal tunnel syndrome, lumbar disc herniation, spondylosis		<i>LIN28B</i> has been associated with bone mineral density (BMD) <sup>41</sup> .
<b>COL10A1</b>	rs7739896	Intron	Myopia	Gonarthrosis, spondylolisthesis	-
<b>EYA4</b>	rs2764217	Intergenic	-	-	Through bone remodelling, <i>EYA4</i> has been found to have an effect on BMD <sup>42</sup> .
<b>FOKX1</b>	rs28658109	Intergenic	-	-	It has been discovered that <i>FOKX1</i> acts via the TGF- $\beta$ pathway and has been associated with BMD <sup>43</sup> . Degenerative diseases of the spine have also been linked to the TGF- $\beta$ pathway <sup>44,45</sup> .
<b>AGMO</b>	rs75674922	Intron	-	-	-
<b>TWIST1</b>	rs2390116	Intron	-	Lumbar disc herniation	<i>TWIST1</i> has been found to be an inflammatory regulator <sup>46</sup> , and has also been associated with lumbar disc herniation (LDH) <sup>47,48</sup> .

<i>JAZF1</i>	rs849135	Intron	Actinic keratosis, basal cell carcinoma	Type II diabetes, asthma, statin medication, coxarthrosis	<i>JAZF1</i> is a transcriptional repressor, which has been associated to height and spine length in addition to lowering IGF-1 serum concentrations <sup>49,50</sup> .
<i>Empty DYNCIII</i>	rs139203647	Intergenic	-	-	-
<i>DYNCIII</i>	rs11769842	Intron	-	-	-
<i>MKX</i>	rs2637326	Intergenic	Low back pain, spondylosis, lumbar disc herniation	Nonsuppurative otitis media	In addition to its well-known function in the development of tendons and ligaments, <i>MKX</i> has been discovered to be a crucial transcription factor in the formation of the intervertebral disc's annulus fibrosus <sup>51,52</sup> . <i>MKX</i> has also previously been associated with LDH <sup>47,48</sup> .
<i>MPPED2</i>	rs607165	Intergenic	Hypertension, cervical disc disorders, arthrosis, spondylosis, depression medications	-	<i>MPPED2</i> regulates many cellular functions, such as differentiation, proliferation, and apoptosis, it also possibly regulates systemic inflammation <sup>53,54</sup> .
<i>PDE3A</i>	rs73067286	Intron	Umbilical hernia	Type II diabetes	-
<i>SOX5</i>	rs12308843	Intron	Arthrosis, lumbar disc herniation, spondylosis, gonarthrosis, low back pain		Transcription factor involved in chondrocytes differentiation and cartilage formation <sup>55-57</sup> .
<i>CCDC91</i>	rs7958415	Regulatory region variant	-	-	<i>CCDC91</i> has been previously associated with OPLL and may have a role in the regulation of osteogenesis <sup>39,58</sup> .
<i>GLII</i>	rs2069506	3 prime UTR variant	-	Lumbar disc herniation	<i>GLII</i> is an activator and is highly expressed in proliferating chondrocytes and the perichondrium adjacent to the prehypertrophic and hypertrophic zones <sup>59</sup> . <i>GLII</i> expression has been found to be increased in hypertrophic ligamentum flavum (LF) and is required for the fibrogenesis of fibroblasts. Hypertrophy of the LF is a significant contributor to LSS <sup>19</sup> .
<i>USP15</i>	rs11174377	Intron	-	-	<i>USP15</i> is an important regulator of TGF-β and BMP-signalling pathways; it modulates an alternative β-catenin pathway that stimulates bone formation, it is also a positive modulator of both TNF-α- and IL-1β- stimulated NF-κB activation <sup>18,60</sup> .
<i>ZCCHC8</i>	rs10846978	Intron	Spondylosis, obesity	-	<i>ZCCHC8</i> is part of the NEXT complex, which regulates mRNA splicing <sup>61</sup> . <i>ZCCHC8</i> has also been found to play a role in the development of the central nervous system <sup>62,63</sup> .
<i>TNFSF11</i>	rs9594751	Intron	-	-	Through bone remodelling, <i>TNFSF11</i> has been found to have an effect on BMD <sup>42</sup> .
<i>SLTRK6</i>	rs9531779	Intergenic	-	-	-
<i>MMP14</i>	rs1042704	Missense	Adhesive capsulitis, dupuytren	Lumbar disc herniation	<i>MMP14</i> missense variant is known to reduce collagen catabolism <sup>64</sup>

			contracture, shoulder lesions, fibroblastic disorders		and through that it can be related to spinal degeneration <sup>65</sup> .
<b>GPR132</b>	rs1022431	Downstream gene variant	-	-	<i>GPR132</i> reduces inflammatory responses by decreasing the number of immune cells and the release of proinflammatory cytokines and growth factors at the site of nerve injury <sup>66</sup> .
<b>ALDHIA2</b>	rs4646570	Intron	Coxarthrosis, polyarthrosis	-	The enzyme retinaldehyde dehydrogenase 2, which is encoded by <i>ALDHIA2</i> , catalyses the conversion of retinaldehyde to retinoic acid, which has a role in maintaining bone and cartilage tissues. <i>ALDHIA2</i> has also been associated with osteoarthritis <sup>67-69</sup> .
<b>PPIB</b>	rs148027154	3 prime UTR variant	-	-	<i>PPIB</i> is involved in procollagen export and secretion <sup>70</sup> . Certain <i>PPIB</i> variants have been found to be associated with osteogenesis imperfecta <sup>71</sup> .
<b>SMAD3</b>	rs4776880	Intron	-	Sciatica, hallux valgus, lumbar disc herniation, spondylosis, cervical disc disorders, coxarthrosis, spondylolisthesis	-
<b>PDE8A</b>	rs11629962	Intron	-	-	<i>PDE8A</i> has a role in T-cell activation <sup>72</sup> , and through the cAMP pathway, it participates in the regulation of many biological pathways <sup>73</sup> .
<b>GAN</b>	rs2966084	Intron	-	Hypertension, type II diabetes	Mutations in the <i>GAN</i> gene cause giant axonal neuropathy, a severe form of sensory and motor neuropathy. Axonal degeneration is accompanied by the accumulation and aggregation of cytoskeletal components. According to these findings, <i>GAN</i> plays a critical role in axonal structure and neuron maintenance <sup>74</sup> .
<b>SOCS7</b>	rs113353816	Intron	-	-	<i>SOCS7</i> regulates a variety of signalling pathways <sup>75</sup> .
<b>AXIN2</b>	rs16961974	Regulatory region variant	Osteoporosis	-	<i>AXIN2</i> is most likely engaged in controlling β-catenin within the Wnt-signaling pathway <sup>76</sup> . The Wnt-signaling pathway is linked to autoimmunity, bone and cartilage regeneration, and repair <sup>77</sup> .
<b>Empty</b>	rs12941198	Intergenic	-	-	-
<b>DCC</b>	rs6508210	Intron	Sciatica, obesity, metabolic disorders, depression, any mental disorder, pain, low back pain, spondylosis, depression medications, lumbar disc herniation	-	<i>DCC</i> might have a role in neurovascular ingrowth/axonal guidance <sup>78,79</sup> .

<b>CACTIN</b>	rs77733715	3 prime UTR variant	Malignant melanoma of skin	-	<i>CACTIN</i> has been associated with longitudinal pediatric bone accrual, it has been annotated to the toll-like receptor pathway which has a role in osteoblast function, including mediating bone inflammatory responses and regulating cell viability, proliferation, and osteoblast-mediated osteoclastogenesis <sup>80</sup> .
<b>CRLF1</b>	rs2074177	Intron	-	-	One frequent cause of LSS is ligamentum flavum hypertrophy <sup>19</sup> . Through the ERK signalling pathway, <i>CRLF1</i> increases LF fibrosis and plays a part in mediating the effects of TGF- $\beta$ 1 <sup>81</sup> .
<b>DDRGK1</b>	rs11697820	Upstream gene variant	-	-	Potentially acting as an NF- $\kappa$ B regulator <sup>82</sup> , <i>DDRGK1</i> can also bind directly to SOX9, preventing its ubiquitination and proteasomal degradation, which can affect the chondrogenesis <sup>83</sup> .
<b>ETS2</b>	rs111901809	Upstream gene variant	-	Atrial fibrillation and flutter, cardiac arrhythmias	Through osteoblast differentiation and bone formation, <i>ETS2</i> potentially plays a role in skeletal development <sup>84</sup> .
<b>OSM</b>	rs2285645	3 prime UTR variant	-	-	<i>OSM</i> is a growth and cytokine production regulator that has been found to have the ability to stimulate bone accrual <sup>85,86</sup> .
<b>CHRD1</b>	rs67648651	Intron	Carpal tunnel syndrome, lumbar disc herniation	Coronary revascularization, hernia, hypercholesterolemia, statin medication, metabolic disorders,	Through its potential to affect the activity of the BMP- and SMAD-signalling pathways, <i>CHRD1</i> may play a significant role in osteogenic differentiation, bone remodelling and neuronal differentiation <sup>87,88</sup> .
<b>Surgical GWAS (FinnGen)</b>					
<b>FOXO1</b>	rs12872985	Intron	Leiomyoma of uterus, lumbar disc herniation	-	In addition to being required for <i>SOX9</i> expression, <i>FOXO1</i> also plays a crucial role in cell-cycle arrest during chondrogenic differentiation through TGF $\beta$ 1 signalling <sup>89</sup> . It also plays a role in B-cell differentiation <sup>30</sup> .

Candidate gene, a gene at a novel locus which biological function is likely to explain the LSS or LSS surgical GWAS association; rsid, SNP markers identification number, Variant type, genomic location of associated variant, PheWAS results for the LSS-associated variants, with an arrow showing the direction of the association. Only associations that reached genome-wide significance ( $p < 5 \times 10^{-8}$ ) are reported.

**Table S4.** The lead variants at 54 LSS-associated ( $p < 5 \times 10^{-8}$ ) loci in the meta-analysis of 30 269 LSS cases and 739 414 controls from FinnGen, the Estonian Biobank, and the UK Biobank. Odds ratios and their 95% confidence intervals for each LSS-associated variant both in the meta-analysis and in each dataset separately. EAF, effect allele frequency.

Candidate gene	CHR:POS	EA	OA	Cohort	OR (95 % CI)	EAF
<i>RUNX3</i>	1:24894533	G	A	Meta-analysis	<b>0.90 (0.88-0.92)</b>	<b>0.31</b>
				FinnGen	0.94 (0.91-0.96)	0.30
				UK Biobank	1.01 (0.97-1.05)	0.32
				Estonian Biobank	0.92 (0.87-0.97)	0.32
<i>NGF</i>	1:115287365	T	C	Meta-analysis	<b>0.93 (0.91-0.95)</b>	<b>0.47</b>
				FinnGen	0.93 (0.91-0.96)	0.47
				UK Biobank	0.92 (0.88-0.96)	0.46
				Estonian Biobank	0.96 (0.92-1.01)	0.47
<i>OTUD7B</i>	1:149934520	C	T	Meta-analysis	<b>0.92 (0.90-0.94)</b>	<b>0.38</b>
				FinnGen	0.91 (0.89-0.94)	0.33
				UK Biobank	0.92 (0.88-0.96)	0.41
				Estonian Biobank	0.93 (0.89-0.98)	0.36
<i>ZNF687</i>	1:151032308	T	C	Meta-analysis	<b>1.21 (1.14-1.27)</b>	<b>0.01</b>
				FinnGen	1.20 (1.13-1.26)	0.03
				UK Biobank	1.71 (0.22-3.21)	0.0002
				Estonian Biobank	1.34 (1.05-1.62)	0.006
<i>PTPRC</i>	1:198819354	C	G	Meta-analysis	<b>0.91 (0.88-0.93)</b>	<b>0.15</b>
				FinnGen	0.90 (0.87-0.93)	0.16
				UK Biobank	0.93 (0.87-0.99)	0.13
				Estonian Biobank	0.90 (0.85-0.96)	0.20
<i>GFPT1</i>	2:69341550	G	A	Meta-analysis	<b>0.91 (0.89-0.93)</b>	<b>0.57</b>
				FinnGen	0.92 (0.89-0.94)	0.55
				UK Biobank	0.91 (0.87-0.95)	0.58
				Estonian Biobank	0.90 (0.86-0.95)	0.58
<i>USP37</i>	2:218486683	G	C	Meta-analysis	<b>0.94 (0.92-0.96)</b>	<b>0.61</b>
				FinnGen	0.94 (0.92-0.96)	0.61
				UK Biobank	-	-
				Estonian Biobank	0.95 (0.91-1.00)	0.62
<i>DAG1</i>	3:49498696	TTTA	T	Meta-analysis	<b>0.95 (0.93-0.97)</b>	<b>0.35</b>
				FinnGen	0.95 (0.92-0.97)	0.44
				UK Biobank	0.95 (0.91-1.00)	0.32
				Estonian Biobank	0.96 (0.91-1.01)	0.30
<i>RAB28</i>	4:12893286	A	AGAG	Meta-analysis	<b>0.92 (0.90-0.94)</b>	<b>0.24</b>
				FinnGen	0.92 (0.89-0.94)	0.25
				UK Biobank	0.91 (0.86-0.95)	0.24
				Estonian Biobank	0.95 (0.90-1.00)	0.23
<i>DAB2</i>	5:39844572	ATATG	A	Meta-analysis	<b>1.08 (1.05-1.10)</b>	<b>0.17</b>
				FinnGen	1.09 (1.06-1.11)	0.19
				UK Biobank	1.05 (0.99-1.10)	0.16
				Estonian Biobank	-	-
<i>ITGA2</i>	5:53038840	A	C	Meta-analysis	<b>1.08 (1.05-1.10)</b>	<b>0.18</b>
				FinnGen	1.07 (1.04-1.10)	0.19
				UK Biobank	1.10 (1.05-1.15)	0.18
				Estonian Biobank	1.08 (1.02-1.14)	0.16
<i>EBF1</i>	5:159017122	G	GC	Meta-analysis	<b>1.06 (1.04-1.09)</b>	<b>0.22</b>
				FinnGen	1.06 (1.03-1.09)	0.17
				UK Biobank	1.07 (1.02-1.12)	0.24
				Estonian Biobank	1.06 (1.01-1.11)	0.27
<i>BMP6</i>	6:7797607	G	C	Meta-analysis	<b>1.08 (1.06-1.11)</b>	<b>0.20</b>
				FinnGen	1.09 (1.06-1.11)	0.22
				UK Biobank	1.09 (1.04-1.14)	0.18
				Estonian Biobank	1.07 (1.01-1.12)	0.19
<i>TRIM38</i>	6:26239176	G	A	Meta-analysis	<b>0.94 (0.93-0.96)</b>	<b>0.32</b>
				FinnGen	0.94 (0.92-0.96)	0.41
				UK Biobank	0.94 (0.89-0.98)	0.26
				Estonian Biobank	0.97 (0.93-1.02)	0.34
<i>HLA</i>	6:30106665	A	T	Meta-analysis	<b>0.94 (0.92-0.96)</b>	<b>0.18</b>
				FinnGen	0.93 (0.90-0.95)	0.23
				UK Biobank	0.95 (0.89-1.01)	0.14
				Estonian Biobank	1.00 (0.94-1.06)	0.16
<i>HLA</i>	6:31133806	A	G	Meta-analysis	<b>0.91 (0.88-0.93)</b>	<b>0.11</b>
				FinnGen	0.89 (0.86-0.92)	0.16
				UK Biobank	0.95 (0.87-1.02)	0.07
				Estonian Biobank	0.95 (0.87-1.02)	0.10
<i>HLA</i>	6:32634706	T	G	Meta-analysis	<b>0.92 (0.90-0.94)</b>	<b>0.20</b>
				FinnGen	0.92 (0.89-0.94)	0.24
				UK Biobank	0.93 (0.88-0.98)	0.18
				Estonian Biobank	-	-
<i>CDC5L</i>	6:44479182	A	C	Meta-analysis	<b>1.07 (1.05-1.08)</b>	<b>0.53</b>
				FinnGen	1.06 (1.04-1.08)	0.53
				UK Biobank	1.10 (1.06-1.14)	0.53
				Estonian Biobank	1.05 (1.01-1.10)	0.53
<i>LIN28B</i>	6:105005542	C	A	Meta-analysis	<b>1.05 (1.03-1.07)</b>	<b>0.57</b>
				FinnGen	1.05 (1.03-1.07)	0.59
				UK Biobank	1.07 (1.03-1.11)	0.56
				Estonian Biobank	1.03 (0.99-1.08)	0.55

<i>COL10A1</i>	6:116167743	G	A	<b>Meta-analysis</b>	<b>0.95 (0.93-0.97)</b>	<b>0.51</b>
				FinnGen	0.95 (0.92-0.97)	0.50
				UK Biobank	0.94 (0.90-0.98)	0.53
				Estonian Biobank	0.98 (0.93-1.02)	0.47
<i>EY44</i>	6:132913577	A	G	<b>Meta-analysis</b>	<b>1.06 (1.05-1.08)</b>	<b>0.43</b>
				FinnGen	1.07 (1.04-1.09)	0.41
				UK Biobank	1.06 (1.02-1.10)	0.44
				Estonian Biobank	-	-
<i>FOXK1</i>	7:4638590	C	T	<b>Meta-analysis</b>	<b>0.93 (0.91-0.96)</b>	<b>0.19</b>
				FinnGen	0.94 (0.91-0.96)	0.23
				UK Biobank	0.92 (0.86-0.97)	0.17
				Estonian Biobank	-	-
<i>AGMO</i>	7:15344063	G	A	<b>Meta-analysis</b>	<b>1.09 (1.06-1.11)</b>	<b>0.13</b>
				FinnGen	1.11 (1.08-1.13)	0.17
				UK Biobank	1.06 (1.00-1.13)	0.11
				Estonian Biobank	1.01 (0.94-1.08)	0.11
<i>TWIST1</i>	7:19488615	T	C	<b>Meta-analysis</b>	<b>0.95 (0.93-0.97)</b>	<b>0.49</b>
				FinnGen	0.95 (0.93-0.97)	0.48
				UK Biobank	0.93 (0.89-0.97)	0.50
				Estonian Biobank	0.97 (0.93-1.02)	0.49
<i>JAZF1</i>	7:28156794	A	G	<b>Meta-analysis</b>	<b>0.95 (0.93-0.97)</b>	<b>0.49</b>
				FinnGen	0.96 (0.94-0.98)	0.47
				UK Biobank	0.94 (.90-0.98)	0.50
				Estonian Biobank	0.93 (0.89-0.98)	0.50
<i>Empty</i>	7:69064281	G	GT	<b>Meta-analysis</b>	<b>1.08 (1.05-1.11)</b>	<b>0.15</b>
				FinnGen	1.08 (1.05-1.11)	0.16
				UK Biobank	1.09 (1.03-1.15)	0.14
				Estonian Biobank	-	-
<i>DYNCIII</i>	7:95941237	C	T	<b>Meta-analysis</b>	<b>1.08 (1.06-1.10)</b>	<b>0.75</b>
				FinnGen	1.08 (1.05-1.10)	0.77
				UK Biobank	1.10 (1.06-1.15)	0.74
				Estonian Biobank	-	-
<i>MKX</i>	10:27612430	T	G	<b>Meta-analysis</b>	<b>1.06 (1.05-1.08)</b>	<b>0.47</b>
				FinnGen	1.05 (1.03-1.08)	0.40
				UK Biobank	1.06 (1.02-1.10)	0.51
				Estonian Biobank	1.11 (1.07-1.16)	0.49
<i>MPPED2</i>	11:30788512	C	T	<b>Meta-analysis</b>	<b>1.05 (1.04-1.07)</b>	<b>0.44</b>
				FinnGen	1.06 (1.04-1.08)	0.48
				UK Biobank	1.04 (1.00-1.08)	0.42
				Estonian Biobank	1.06 (1.10-1.10)	0.43
<i>PDE3A</i>	12:20427791	A	T	<b>Meta-analysis</b>	<b>0.93 (0.91-0.95)</b>	<b>0.23</b>
				FinnGen	0.93 (0.90-0.95)	0.26
				UK Biobank	0.91 (0.86-0.95)	0.21
				Estonian Biobank	0.94 (0.90-0.99)	0.31
<i>SOX5</i>	12:23821470	C	G	<b>Meta-analysis</b>	<b>1.08 (1.06-1.10)</b>	<b>0.27</b>
				FinnGen	1.07 (1.05-1.10)	0.31
				UK Biobank	1.08 (1.03-1.12)	0.23
				Estonian Biobank	1.10 (1.05-1.15)	0.32
<i>CCDC9I</i>	12:27844985	T	C	<b>Meta-analysis</b>	<b>0.93 (0.91-0.95)</b>	<b>0.35</b>
				FinnGen	0.93 (0.91-0.95)	0.31
				UK Biobank	0.94 (0.90-0.98)	0.38
				Estonian Biobank	0.93 (0.89-0.98)	0.39
<i>GLII</i>	12:57749071	A	C	<b>Meta-analysis</b>	<b>0.94 (0.93-0.96)</b>	<b>0.33</b>
				FinnGen	0.92 (0.88-0.95)	0.34
				UK Biobank	0.97 (0.91-1.02)	0.32
				Estonian Biobank	0.94 (0.88-1.01)	0.36
<i>USP15</i>	12:62218131	A	G	<b>Meta-analysis</b>	<b>1.07 (1.05-1.10)</b>	<b>0.17</b>
				FinnGen	1.07 (1.04-1.10)	0.17
				UK Biobank	1.10 (1.04-1.15)	0.16
				Estonian Biobank	1.07 (1.01-1.13)	0.18
<i>ZCCHC8</i>	12:122480161	C	T	<b>Meta-analysis</b>	<b>1.06 (1.04-1.09)</b>	<b>0.77</b>
				FinnGen	1.05 (1.02-1.08)	0.80
				UK Biobank	1.09 (1.04-1.13)	0.74
				Estonian Biobank	1.06 (1.01-1.12)	0.76
<i>TNFSF11</i>	13:42423131	T	C	<b>Meta-analysis</b>	<b>0.95 (0.93-0.97)</b>	<b>0.25</b>
				FinnGen	0.94 (0.92-0.96)	0.27
				UK Biobank	0.93 (0.88-0.97)	0.23
				Estonian Biobank	0.99 (0.94-1.04)	0.27
<i>SLTRK6</i>	13:85356178	G	C	<b>Meta-analysis</b>	<b>0.94 (0.93-0.96)</b>	<b>0.59</b>
				FinnGen	0.94 (0.92-0.96)	0.59
				UK Biobank	0.93 (0.89-0.97)	0.60
				Estonian Biobank	0.97 (0.93-1.02)	0.54
<i>MMP14</i>	14:22843385	A	G	<b>Meta-analysis</b>	<b>0.93 (0.91-0.96)</b>	<b>0.21</b>
				FinnGen	0.93 (0.90-0.96)	0.21
				UK Biobank	0.94 (0.89-0.99)	0.21
				Estonian Biobank	0.95 (0.90-1.00)	0.21
<i>GPR132</i>	14:105137078	A	C	<b>Meta-analysis</b>	<b>0.91 (0.88-0.95)</b>	<b>0.09</b>
				FinnGen	0.90 (0.86-0.94)	0.07
				UK Biobank	0.93 (0.87-1.00)	0.11
				Estonian Biobank	0.92 (0.84-1.01)	0.09
<i>ALDHIA2</i>	15:58050948	C	G	<b>Meta-analysis</b>	<b>1.06 (1.05-1.08)</b>	<b>0.49</b>

				FinnGen	1.07 (1.04-1.09)	0.49
				UK Biobank	1.06 (1.02-1.10)	0.49
				Estonian Biobank	1.05 (1.01-1.10)	0.47
<i>PPIB</i>	15:64138226	A	T	<b>Meta-analysis</b>	<b>1.28 (1.20-1.37)</b>	<b>0.006</b>
				FinnGen	1.27 (1.18-1.36)	0.01
				UK Biobank	2.12 (1.02-1.10)	0.002
				Estonian Biobank	1.22 (0.80-1.64)	0.003
<i>SMAD3</i>	15:67072653	A	G	<b>Meta-analysis</b>	<b>0.90 (0.88-0.92)</b>	<b>0.35</b>
				FinnGen	0.91 (0.89-0.93)	0.37
				UK Biobank	0.88 (0.84-0.92)	0.33
				Estonian Biobank	0.89 (0.85-0.94)	0.41
<i>PDE8A</i>	15:84986797	T	C	<b>Meta-analysis</b>	<b>0.94 (0.92-0.96)</b>	<b>0.25</b>
				FinnGen	0.93 (0.91-0.96)	0.27
				UK Biobank	0.96 (0.92-1.01)	0.24
				Estonian Biobank	-	-
<i>GAN</i>	16:81482778	G	A	<b>Meta-analysis</b>	<b>0.94 (0.92-0.96)</b>	<b>0.69</b>
				FinnGen	0.94 (0.92-0.96)	0.67
				UK Biobank	0.93 (0.88-0.97)	0.71
				Estonian Biobank	0.95 (0.90-1.00)	0.72
<i>SOCS7</i>	17:38474030	C	T	<b>Meta-analysis</b>	<b>1.06 (1.04-1.09)</b>	<b>0.83</b>
				FinnGen	1.08 (1.05-1.10)	0.79
				UK Biobank	1.02 (0.97-1.08)	0.86
				Estonian Biobank	1.06 (1.00-1.12)	0.81
<i>AXIN2</i>	17:65278900	C	T	<b>Meta-analysis</b>	<b>1.06 (1.04-1.07)</b>	<b>0.28</b>
				FinnGen	1.06 (1.03-1.08)	0.29
				UK Biobank	1.03 (0.98-1.08)	0.26
				Estonian Biobank	1.07 (1.03-1.12)	0.36
<i>Empty</i>	17:71476022	C	A	<b>Meta-analysis</b>	<b>1.06 (1.04-1.08)</b>	<b>0.78</b>
				FinnGen	1.06 (1.03-1.09)	0.78
				UK Biobank	1.09 (1.05-1.14)	0.78
				Estonian Biobank	1.03 (0.98-1.08)	0.78
<i>DCC</i>	18:53220821	C	A	<b>Meta-analysis</b>	<b>1.08 (1.06-1.09)</b>	<b>0.52</b>
				FinnGen	1.08 (1.06-1.10)	0.49
				UK Biobank	1.07 (1.03-1.11)	0.53
				Estonian Biobank	1.05 (1.01-1.10)	0.56
<i>CACTIN</i>	19:3537186	G	A	<b>Meta-analysis</b>	<b>1.14 (1.09-1.18)</b>	<b>0.03</b>
				FinnGen	1.15 (1.10-1.19)	0.05
				UK Biobank	1.22 (1.00-1.43)	0.009
				Estonian Biobank	1.06 (0.92-1.19)	0.03
<i>CRLF1</i>	19:18616479	G	A	<b>Meta-analysis</b>	<b>0.93 (0.91-0.95)</b>	<b>0.25</b>
				FinnGen	0.93 (0.90-0.95)	0.25
				UK Biobank	0.91 (0.86-0.96)	0.24
				Estonian Biobank	0.96 (0.90-1.01)	0.26
<i>DDRGK1</i>	20:2800795	T	C	<b>Meta-analysis</b>	<b>0.95 (0.93-0.96)</b>	<b>0.58</b>
				FinnGen	0.95 (0.93-0.97)	0.58
				UK Biobank	0.92 (0.88-0.96)	0.59
				Estonian Biobank	0.96 (0.91-1.00)	0.56
<i>ETS2</i>	21:39183865	T	TAGAGGGGCA GGGGCG	<b>Meta-analysis</b>	<b>1.05 (1.03-1.07)</b>	<b>0.49</b>
				FinnGen	1.04 (1.02-1.07)	0.56
				UK Biobank	1.09 (1.05-1.13)	0.44
				Estonian Biobank	1.04 (0.99-1.08)	0.53
<i>OSM</i>	22:30026719	T	C	<b>Meta-analysis</b>	<b>0.83 (0.78-0.89)</b>	<b>0.02</b>
				FinnGen	0.83 (0.78-0.89)	0.05
				UK Biobank	0.76 (0.15-1.37)	0.001
				Estonian Biobank	0.84 (0.68-1.01)	0.02
<i>CHRD1</i>	X:110450046	C	T	<b>Meta-analysis</b>	<b>1.05 (1.04-1.07)</b>	<b>0.40</b>
				FinnGen	1.05 (1.03-1.06)	0.38
				UK Biobank	1.07 (1.04-1.10)	0.41
				Estonian Biobank	1.06 (1.02-1.10)	0.39

**Table S5.** Meta-analysis and surgical GWAS effect differences for every LSS-associated variant. Two-tailed test was used for statistical testing, for that we used following formula:  $((Effect\_Meta-Effect\_SURG)/\sqrt{standarderror\_Meta^2+standarderror\_SURG^2})$ ,  $P_{diff}=2*(1-dif)$ .  $P_{diff} < 0.05$  was considered as a threshold for statistical significance.

Candidate gene	rsid	Effect Meta	Effect SURG	Standard error Meta	Standard error SURG	P_diff
<i>RUNX3</i>	rs9438857	-0,053	-0,086	0,010	0,017	0,101
<i>NGF</i>	<b>rs6327</b>	<b>-0,072</b>	<b>-0,109</b>	<b>0,009</b>	<b>0,016</b>	<b>0,042</b>
<i>OTUD7B</i>	rs11205303	-0,085	-0,118	0,009	0,017	0,100
<i>ZNF687</i>	rs147042690	0,188	0,211	0,033	0,047	0,691
<i>PTPRC</i>	rs72739729	-0,097	-0,121	0,012	0,022	0,337
<i>GFPT1</i>	rs4340572	-0,092	-0,109	0,009	0,016	0,337
<i>USP37</i>	rs60362609	-0,057	-0,063	0,010	0,016	0,771
<i>DAG1</i>	rs138073019	-0,053	-0,062	0,009	0,016	0,629
<i>RAB28</i>	<b>rs5856174</b>	<b>-0,082</b>	<b>-0,125</b>	<b>0,010</b>	<b>0,019</b>	<b>0,043</b>
<i>ITGA2</i>	rs148346348	0,076	0,095	0,012	0,020	0,431
<i>DAB2</i>	rs11747379	0,074	0,079	0,011	0,020	0,805
<i>EBF1</i>	rs200608668	0,062	0,070	0,011	0,021	0,707
<i>BMP6</i>	<b>rs10498672</b>	<b>0,081</b>	<b>0,143</b>	<b>0,011</b>	<b>0,019</b>	<b>0,004</b>
<i>TRIM38</i>	<b>rs9358913</b>	<b>-0,057</b>	<b>-0,093</b>	<b>0,009</b>	<b>0,016</b>	<b>0,049</b>
<i>HLA</i>	rs62390186	-0,062	-0,100	0,011	0,019	0,085
<i>HLA</i>	rs4294047	-0,097	-0,112	0,013	0,022	0,573
<i>HLA</i>	rs17205170	-0,085	-0,086	0,012	0,019	0,953
<i>CDC5L</i>	rs7770012	0,064	0,082	0,009	0,016	0,305
<i>LIN28B</i>	rs314261	0,050	0,061	0,009	0,016	0,576
<i>COL10A1</i>	rs7739896	-0,052	-0,082	0,009	0,016	0,095
<i>EYA4</i>	rs2764217	0,063	0,068	0,010	0,016	0,781
<i>FOKX1</i>	rs28658109	-0,068	-0,058	0,012	0,019	0,651
<i>AGMO</i>	<b>rs75674922</b>	<b>0,085</b>	<b>0,135</b>	<b>0,012</b>	<b>0,020</b>	<b>0,038</b>
<i>TWIST1</i>	rs2390116	-0,050	-0,066	0,009	0,016	0,364
<i>JAZF1</i>	rs849135	-0,052	-0,060	0,009	0,016	0,658
<i>Empty</i>	rs139203647	0,076	0,090	0,013	0,021	0,579
<i>DYNCIII</i>	rs11769842	0,079	0,079	0,012	0,019	0,999
<i>MKX</i>	rs2637326	0,063	0,062	0,009	0,016	0,992
<i>MPPED2</i>	rs607165	0,053	0,048	0,009	0,016	0,748
<i>PDE3A</i>	rs73067286	-0,076	-0,086	0,010	0,018	0,609
<i>SOX5</i>	rs12308843	0,077	0,057	0,010	0,017	0,308
<i>CCDC91</i>	rs7958415	-0,071	-0,084	0,010	0,017	0,493
<i>GLII</i>	rs2069506	-0,057	-0,093	0,009	0,017	0,057
<i>USP15</i>	rs11174377	0,070	0,070	0,012	0,021	1,000
<i>ZCCHC8</i>	rs10846978	0,059	0,039	0,011	0,020	0,358
<i>TNFSF11</i>	<b>rs9594751</b>	<b>-0,056</b>	<b>-0,100</b>	<b>0,010</b>	<b>0,018</b>	<b>0,037</b>
<i>LINC00351</i>	rs9531779	-0,058	-0,070	0,009	0,016	0,518
<i>MMP14</i>	rs1042704	-0,068	-0,079	0,011	0,020	0,619
<i>GPR132</i>	rs1022431	-0,091	-0,139	0,017	0,031	0,166
<i>ALDHIA2</i>	<b>rs4646570</b>	<b>0,061</b>	<b>0,104</b>	<b>0,009</b>	<b>0,016</b>	<b>0,018</b>
<i>PPIB</i>	rs148027154	0,250	0,262	0,045	0,067	0,884
<i>SMAD3</i>	rs4776880	-0,103	-0,100	0,009	0,016	0,860
<i>PDE8A</i>	rs11629962	-0,062	-0,089	0,011	0,018	0,190
<i>GAN</i>	rs2966084	-0,063	-0,068	0,010	0,017	0,813
<i>SOCS7</i>	rs113353816	0,063	0,081	0,011	0,020	0,425
<i>AXIN2</i>	rs16961974	0,054	0,063	0,010	0,017	0,651
<i>Empty</i>	rs12941198	0,059	0,053	0,011	0,019	0,780
<i>DCC</i>	rs6508210	0,073	0,075	0,009	0,016	0,926
<i>CACTIN</i>	rs77733715	0,130	0,187	0,023	0,035	0,171
<i>CRLF1</i>	rs2074177	-0,074	-0,092	0,010	0,019	0,407
<i>DDRGK1</i>	rs11697820	-0,056	-0,054	0,009	0,016	0,920
<i>ETS2</i>	rs111901809	0,049	0,042	0,009	0,016	0,687
<i>OSM</i>	rs2285645	-0,181	-0,244	0,026	0,040	0,192
<i>CHRDL1</i>	rs67648651	0,051	0,060	0,008	0,013	0,564

**Table S6.** FastBAT gene prioritisation results, that we obtained from analysis performed with GCTA software<sup>90</sup>. For loci we used 2MB window and for LD reference we used FinnGen. We considered results with pFASTBAT<5x10<sup>-8</sup> and pgWAS<5x10<sup>-8</sup> significant<sup>91</sup>.

Chr	Gene	pFASTBAT	pGWAS	TopSNP
1	FAM72C	1.80416e-08	1.76e-19	chr1_149934520_T_C
1	MTMR11	4.79029e-11	4.54e-17	chr1_149920979_A_G
1	OTUD7B	7.38031e-17	1.76e-19	chr1_149934520_T_C
1	SF3B4	1.83939e-11	4.54e-17	chr1_149920979_A_G
1	SRGAP2D	1.76634e-08	1.76e-19	chr1_149934520_T_C
1	VPS45	8.59157e-12	1.51e-18	chr1_150023307_G_A
1	FAM72C	4.04694e-11	2.18e-15	chr1_198819354_G_C
1	SRGAP2D	4.04694e-11	2.18e-15	chr1_198819354_G_C
2	ANTXR1	1.09116e-15	3.45e-21	chr2_69418633_C_A
2	ARHGAP25	5.51267e-14	7.86e-25	chr2_69322904_T_C
2	BMP10	1.80052e-21	5.64e-25	chr2_69341550_A_G
2	GKN1	7.54269e-18	1.5e-21	chr2_69406431_G_GA
2	GKN2	2.23381e-20	6.31e-25	chr2_69352523_C_G
2	ANTXR1	6.32123e-15	1.99e-19	chr2_69433082_G_A
2	GKN1	2.75363e-17	1.99e-19	chr2_69433082_G_A
2	GKN2	1.58446e-15	1.99e-19	chr2_69433082_G_A
3	AMT	1.5124e-08	9.31e-09	chr3_49498696_T_TTTA
3	BSN	4.84111e-09	1.08e-08	chr3_49629531_C_A
3	DAG1	9.3841e-09	9.31e-09	chr3_49498696_T_TTTA
3	GPX1	4.34351e-09	1.21e-08	chr3_49408664_G_GTATA
3	NICN1	7.8823e-09	9.31e-09	chr3_49498696_T_TTTA
3	RHOA	3.89366e-09	9.31e-09	chr3_49498696_T_TTTA
3	TCTA	5.76385e-09	9.31e-09	chr3_49498696_T_TTTA
6	MOXD1	2.50626e-09	1.36e-10	chr6_132913577_G_A
6	BTN3A2	4.16556e-08	3.27e-09	chr6_26353699_A_G
6	BMP6	8.56593e-11	9.09e-14	chr6_7797607_C_G
7	AGMO	1.50745e-11	6.72e-12	chr7_15344063_A_G
7	JAZF1	4.21504e-08	7.32e-09	chr7_28156794_G_A
7	SHFM1	2.66193e-09	1.18e-11	chr7_95941237_T_C
11	DCDC5	4.8859e-08	3.23e-09	chr11_30877762_C_T
12	KDM2B	4.68808e-08	4.49e-08	chr12_122480161_T_C
12	SOX5	3.0539e-10	3.3e-15	chr12_23821470_G_C
12	KLHL42	1.78641e-09	8.41e-12	chr12_28109762_G_GT
12	MANSC4	1.97722e-09	8.41e-12	chr12_28109762_G_GT
12	MRPS35	7.05575e-09	8.41e-12	chr12_28109762_G_GT
12	PPFIBP1	3.18281e-11	1.07e-13	chr12_27844985_C_T
12	SMCO2	3.30074e-08	1.07e-13	chr12_27844985_C_T
12	KLHL42	1.78641e-09	8.41e-12	chr12_28109762_G_GT
12	MANSC4	1.97722e-09	8.41e-12	chr12_28109762_G_GT
12	MRPS35	7.05575e-09	8.41e-12	chr12_28109762_G_GT
12	HSD17B6	2.42438e-08	2.59e-08	chr12_57608816_C_T
12	MYO1A	5.15097e-09	7.37e-09	chr12_57768302_G_T
12	RDH16	4.13935e-08	1.56e-09	chr12_57749071_C_A
12	SDR9C7	2.48397e-08	1.56e-09	chr12_57749071_C_A
12	TAC3	8.61341e-09	1.56e-09	chr12_57749071_C_A
12	ZBTB39	2.4375e-08	1.56e-09	chr12_57749071_C_A
15	CGNL1	3.63258e-09	5.47e-12	chr15_58050948_G_C
15	LCTL	7.2707e-10	4.6e-13	chr15_67085695_A_G
15	MAP2K1	1.50604e-23	1.05e-28	chr15_67072653_G_A
15	RPL4	1.98261e-30	1.05e-28	chr15_67072653_G_A
15	SCARNA14	2.38228e-08	2.38e-10	chr15_66975565(CG)C
15	SNAPC5	2.68647e-29	1.05e-28	chr15_67072653_G_A
15	TIPIN	1.89533e-08	6.13e-11	chr15_66991209_C_A
15	ZWILCH	5.50651e-22	1.05e-28	chr15_67072653_G_A
17	CASKIN2	1.82154e-09	3.6e-08	chr17_71476022_A_C
17	LLGL2	1.12465e-09	3.6e-08	chr17_71476022_A_C
17	TSEN54	2.68638e-09	3.6e-08	chr17_71476022_A_C
18	ATP8B1	6.87157e-10	3.76e-14	chr18_53170750_C_T
18	NEDD4L	4.54904e-10	7.36e-14	chr18_53344021_T_A
19	IFI30	4.87103e-08	2.98e-08	chr19_18381183_G_A
19	LSM4	1.28778e-09	2.19e-10	chr19_18591691_G_A
19	MPV17L2	1.31597e-08	2.98e-08	chr19_18381183_G_A
19	PDE4C	8.52371e-09	2.98e-08	chr19_18381183_G_A
19	PGPEP1	5.8441e-09	1.03e-12	chr19_18616479_A_G
19	RAB3A	8.4324e-09	2.98e-08	chr19_18381183_G_A
20	C20orf141	1.37456e-08	5.15e-10	chr20_2800795_C_T
20	CPXM1	1.38587e-08	5.15e-10	chr20_2800795_C_T
20	PCED1A	1.32913e-08	5.15e-10	chr20_2800795_C_T
20	TMEM239	1.24452e-08	5.15e-10	chr20_2800795_C_T
20	VPS16	1.23202e-08	5.15e-10	chr20_2800795_C_T

**Table S7.** We investigated eQTL colocalizations between LSS association signals and gene expression using the 'coloc.abf' function from the R-library coloc<sup>92</sup>. The 'biomaRt' R-library was used to extract genes from Ensembl archives<sup>93</sup> within a 1 MB ( $\pm 500000$ ) window surrounding each lead variant. Colocalizations were investigated for 754 genes that were available in GTEx. We chose tissues relevant to LSS for analysis, including the tibial nerve, cervical spinal cord, and whole blood. For the selected tissues, data on variant-gene expression associations (GTEx v8) were downloaded from GTExportal<sup>7</sup>. Colocalizations with a posterior probability of  $\geq 0.8$  for the shared variant (PP4) were deemed significant<sup>94</sup>.

Tissue	Gene_id	Gene	PP0	PP1	PP2	PP3	PP4
Whole_Blood	ENSG00000198380.12	<i>GFP71</i>	2.49e-36	1.05e-20	3.17e-17	0.133	0.867
Whole_Blood	ENSG00000135913.10	<i>USP37</i>	3.47e-09	6.07e-05	6.15e-06	0.107	0.893
Whole_Blood	ENSG00000144580.13	<i>CNOT9</i>	8.89e-42	4.66e-05	1.58e-38	0.082	0.918
Whole_Blood	ENSG00000178467.17	<i>P4HTM</i>	3.9e-05	0.049	9.93e-05	0.123	0.829
Whole_Blood	ENSG00000164062.12	<i>APEH</i>	3.73e-05	3.58e-05	0.085	0.08	0.835
Whole_Blood	ENSG00000173531.15	<i>MST1</i>	0.001	0.022	0.006	0.095	0.875
Whole_Blood	ENSG00000197409.7	<i>HIST1H3D</i>	0.000363	0.000388	0.008	0.008	0.984
Whole_Blood	ENSG00000276966.2	<i>HIST1H4E</i>	7.21e-05	2.55e-05	0.013	0.004	0.983
Whole_Blood	ENSG00000124549.14	<i>BTN2A3P</i>	0.005	0.01	0.032	0.06	0.891
Whole_Blood	ENSG00000204610.12	<i>TRIM15</i>	1.02e-06	0.004	4.58e-05	0.19	0.806
Whole_Blood	ENSG00000228022.5	<i>HCG20</i>	1.43e-08	3.63e-06	3.73e-05	0.008	0.991
Whole_Blood	ENSG00000137310.11	<i>TCF19</i>	4.87e-25	2.55e-09	2.21e-17	0.115	0.885
Whole_Blood	ENSG00000204472.12	<i>AIF1</i>	3.03e-11	0.016	3.61e-11	0.018	0.967
Whole_Blood	ENSG00000247934.4	<i>RP11-967K21.1</i>	2.08e-06	0.004	4.78e-05	0.08	0.917
Whole_Blood	ENSG00000123427.16	<i>METTL21B</i>	2.81e-81	1.71e-05	1.12e-77	0.068	0.932
Whole_Blood	ENSG00000123297.17	<i>TSFM</i>	5.98e-06	1.48e-05	0.018	0.044	0.939
Whole_Blood	ENSG00000033030.13	<i>ZCCHC8</i>	0.037	0.018	0.03	0.014	0.9
Whole_Blood	ENSG00000111011.17	<i>RSRC2</i>	2.04e-07	0.000427	6.97e-05	0.145	0.855
Whole_Blood	ENSG00000150967.17	<i>ABCB9</i>	7.04e-05	0.015	0.00061	0.128	0.856
Whole_Blood	ENSG00000129562.10	<i>DAD1</i>	2.09e-13	0.179	4.71e-15	0.003	0.818
Whole_Blood	ENSG00000172590.18	<i>MRPL52</i>	2.35e-10	2.37e-06	5.07e-07	0.004	0.996
Whole_Blood	ENSG00000108370.16	<i>RGS9</i>	0.076	0.072	0.017	0.016	0.818
Whole_Blood	ENSG00000183397.5	<i>TEKTIP1</i>	2.06e-18	0.127	4.21e-19	0.025	0.848
Whole_Blood	ENSG00000130517.13	<i>PGPEPI</i>	1.13e-12	0.000281	1.76e-10	0.043	0.957
Whole_Blood	ENSG00000105655.18	<i>ISYNA1</i>	0.001	0.025	0.008	0.136	0.83
Whole_Blood	ENSG00000132670.20	<i>PTPRA</i>	0.000581	0.004	0.007	0.048	0.941
Whole_Blood	ENSG00000255568.3	<i>BRWD1-AS2</i>	3.61e-08	0.000268	1.22e-05	0.09	0.91
Whole_Blood	ENSG00000205581.10	<i>HMGNI</i>	0.00033	0.028	0.002	0.16	0.81
Cells_Cultured_fibroblasts	ENSG00000270882.2	<i>HIST2H4A</i>	6.39e-05	2.08e-06	0.11	0.003	0.887
Cells_Cultured_fibroblasts	ENSG00000261716.1	<i>RP11-196G18.22</i>	8.45e-16	4.4e-14	0.003	0.176	0.821
Cells_Cultured_fibroblasts	ENSG0000014914.20	<i>MTMR11</i>	1.7e-11	4.18e-09	5.98e-06	0.000471	1
Cells_Cultured_fibroblasts	ENSG00000135913.10	<i>USP37</i>	5.09e-06	6.28e-05	0.009	0.108	0.883
Cells_Cultured_fibroblasts	ENSG00000115556.13	<i>PLCD4</i>	1.31e-25	6.42e-05	2.32e-22	0.113	0.887
Cells_Cultured_fibroblasts	ENSG00000115568.15	<i>ZNF142</i>	2.82e-06	7.9e-05	0.005	0.137	0.858
Cells_Cultured_fibroblasts	ENSG00000178467.17	<i>P4HTM</i>	1.31e-26	0.046	3.78e-26	0.132	0.822
Cells_Cultured_fibroblasts	ENSG00000198218.10	<i>QRICH1</i>	0.026	0.062	0.027	0.063	0.823
Cells_Cultured_fibroblasts	ENSG00000235908.1	<i>RHOA-IT1</i>	6.28e-06	3.23e-05	0.02	0.101	0.879
Cells_Cultured_fibroblasts	ENSG00000164330.16	<i>EBF1</i>	6.73e-05	0.003	0.001	0.047	0.949
Cells_Cultured_fibroblasts	ENSG00000145860.11	<i>RNF145</i>	0.037	0.019	0.047	0.023	0.874
Cells_Cultured_fibroblasts	ENSG00000228022.5	<i>HCG20</i>	1.04e-21	3.18e-06	3.55e-18	0.01	0.99
Cells_Cultured_fibroblasts	ENSG00000204314.10	<i>PRRT1</i>	2.49e-05	0.01	8.27e-05	0.032	0.957
Cells_Cultured_fibroblasts	ENSG00000221988.12	<i>PPT2</i>	4.09e-05	0.024	0.000144	0.083	0.894
Cells_Cultured_fibroblasts	ENSG00000204308.7	<i>RNF5</i>	2.02e-07	0.004	9.91e-06	0.195	0.801
Cells_Cultured_fibroblasts	ENSG00000204305.13	<i>AGER</i>	1.27e-11	0.007	9.08e-11	0.047	0.947
Cells_Cultured_fibroblasts	ENSG00000204301.6	<i>NOTCH4</i>	2.25e-08	2.39e-08	0.081	0.085	0.833
Cells_Cultured_fibroblasts	ENSG00000204287.13	<i>HLA-DRA</i>	0.003	0.000956	0.041	0.011	0.944
Cells_Cultured_fibroblasts	ENSG00000179912.20	<i>R3HDM2</i>	0.015	0.071	0.016	0.074	0.824
Cells_Cultured_fibroblasts	ENSG00000111012.9	<i>CYP27B1</i>	7.03e-08	1.36e-05	0.000277	0.052	0.947
Cells_Cultured_fibroblasts	ENSG00000123427.16	<i>METTL21B</i>	2.54e-152	1.62e-05	1.02e-148	0.064	0.936
Cells_Cultured_fibroblasts	ENSG00000123297.17	<i>TSFM</i>	8.3e-208	1.39e-05	3.32e-204	0.055	0.945
Cells_Cultured_fibroblasts	ENSG00000245651.2	<i>RP11-620J15.2</i>	0.001	0.000443	0.055	0.017	0.926
Cells_Cultured_fibroblasts	ENSG00000273805.1	<i>RP11-620J15.4</i>	0.038	0.025	0.043	0.028	0.866
Cells_Cultured_fibroblasts	ENSG0000023516.8	<i>AKAP11</i>	0.00029	0.004	0.002	0.023	0.971
Cells_Cultured_fibroblasts	ENSG00000129562.10	<i>DAD1</i>	0.013	0.09	0.000211	0.000525	0.896
Cells_Cultured_fibroblasts	ENSG00000157227.12	<i>MMP14</i>	0.000106	0.01	8.56e-05	0.007	0.982
Cells_Cultured_fibroblasts	ENSG00000137834.14	<i>SMAD6</i>	0.022	0.012	0.036	0.019	0.911
Cells_Cultured_fibroblasts	ENSG00000276170.4	<i>AC124789.1</i>	0.000557	0.000869	0.011	0.016	0.971
Cells_Cultured_fibroblasts	ENSG00000183397.5	<i>TEKTIP1</i>	8.19e-05	0.099	5.73e-06	0.006	0.895

Cells_Cultured_fibroblasts	ENSG00000130513.6	<i>GDF15</i>	0.02	0.018	0.01	0.008	0.945
Cells Cultured fibroblasts	ENSG00000088882.7	<i>CPXM1</i>	3.56e-08	1.99e-05	4.03e-05	0.022	0.978
Cells Cultured fibroblasts	ENSG00000235701.1	<i>PCBP2P1</i>	4.08e-06	0.000411	0.002	0.158	0.84
Cells Cultured fibroblasts	ENSG00000255568.3	<i>BRWD1-AS2</i>	5.96e-08	0.000261	1.76e-05	0.076	0.924
Nerve Tibial	ENSG00000014914.20	<i>MTMR11</i>	7.07e-09	2.44e-08	0.003	0.008	0.99
Nerve Tibial	ENSG00000081237.18	<i>PTPRC</i>	6.97e-07	1.34e-06	0.046	0.087	0.867
Nerve Tibial	ENSG00000169604.19	<i>ANTXR1</i>	1.35e-09	5.23e-09	0.023	0.088	0.889
Nerve Tibial	ENSG00000169599.12	<i>NFUJ1</i>	6.43e-23	8.79e-21	0.000817	0.111	0.888
Nerve Tibial	ENSG00000135913.10	<i>USP37</i>	6.18e-13	0.000103	1.1e-09	0.181	0.819
Nerve Tibial	ENSG00000115556.13	<i>PLCD4</i>	1.74e-07	9.02e-05	0.000302	0.156	0.844
Nerve Tibial	ENSG00000115568.15	<i>ZNF142</i>	1.13e-05	0.005	0.000303	0.143	0.852
Nerve Tibial	ENSG00000270441.1	<i>RP11-694I15.7</i>	0.002	0.055	0.003	0.067	0.873
Nerve Tibial	ENSG00000164062.12	<i>APEH</i>	5.48e-10	5.6e-05	1.77e-06	0.18	0.82
Nerve Tibial	ENSG00000164171.10	<i>ITGA2</i>	5.77e-06	0.009	1.34e-05	0.021	0.97
Nerve Tibial	ENSG00000239264.8	<i>TXND5</i>	1.76e-10	0.021	1.69e-10	0.019	0.96
Nerve Tibial	ENSG00000228022.5	<i>HCG20</i>	2.56e-16	3.15e-06	6.7e-13	0.007	0.993
Nerve Tibial	ENSG00000168631.12	<i>DPCR1</i>	8.79e-24	0.001	9.55e-22	0.117	0.882
Nerve Tibial	ENSG00000204498.10	<i>NFKBIL1</i>	2.49e-05	2.33e-05	0.006	0.005	0.989
Nerve Tibial	ENSG00000204472.12	<i>AIF1</i>	0.075	0.036	0.019	0.008	0.861
Nerve Tibial	ENSG00000204256.12	<i>BRD2</i>	1.83e-05	0.005	0.000553	0.138	0.857
Nerve Tibial	ENSG00000111816.7	<i>FRK</i>	0.001	0.004	0.012	0.047	0.936
Nerve Tibial	ENSG00000200534.1	<i>SNORA33</i>	0.009	0.051	0.015	0.079	0.846
Nerve Tibial	ENSG00000187546.13	<i>AGMO</i>	0.007	0.001	0.091	0.012	0.889
Nerve Tibial	ENSG00000153814.11	<i>JAZF1</i>	1.05e-10	5.59e-05	5.79e-08	0.03	0.97
Nerve Tibial	ENSG00000066382.16	<i>MPPED2</i>	2.24e-06	2.48e-05	0.012	0.132	0.856
Nerve Tibial	ENSG00000166908.17	<i>PIP4K2C</i>	0.000103	0.000483	0.014	0.063	0.923
Nerve Tibial	ENSG00000135506.15	<i>OS9</i>	0.000573	0.021	0.004	0.142	0.832
Nerve Tibial	ENSG00000135452.9	<i>TSPAN31</i>	1.04e-05	1.65e-05	0.03	0.047	0.923
Nerve Tibial	ENSG00000135446.16	<i>CDK4</i>	1.61e-05	0.000158	0.013	0.128	0.858
Nerve Tibial	ENSG00000111012.9	<i>CYP27B1</i>	2.31e-06	1.51e-05	0.008	0.051	0.941
Nerve Tibial	ENSG00000123427.16	<i>METTL21B</i>	9.51e-57	1.64e-05	3.81e-53	0.065	0.935
Nerve Tibial	ENSG00000123297.17	<i>TSFM</i>	6.28e-21	1.25e-05	2.52e-17	0.049	0.951
Nerve Tibial	ENSG00000033030.13	<i>ZCCHC8</i>	0.013	0.002	0.056	0.009	0.92
Nerve Tibial	ENSG00000184445.11	<i>KNTC1</i>	2.37e-06	0.091	5.68e-07	0.021	0.888
Nerve Tibial	ENSG00000103657.13	<i>HERC1</i>	0.043	0.099	0.004	0.009	0.845
Nerve Tibial	ENSG00000259347.6	<i>RP11-798K3.2</i>	2.77e-12	5.79e-13	0.043	0.008	0.949
Nerve Tibial	ENSG00000105325.13	<i>FZRI</i>	2.73e-18	0.097	6.55e-19	0.022	0.88
Nerve Tibial	ENSG00000183397.5	<i>TEKTIP1</i>	1.33e-27	0.14	3.81e-28	0.039	0.821
Nerve Tibial	ENSG00000255568.3	<i>BRWD1-AS2</i>	1.56e-07	0.00034	4.6e-05	0.099	0.9
Brain_Spinal_cord_cervical_c-1	ENSG00000178467.17	<i>P4HTM</i>	5.38e-07	0.051	1.5e-06	0.141	0.808
Brain_Spinal_cord_cervical_c-1	ENSG00000178252.17	<i>WDR6</i>	2.72e-05	0.055	6.69e-05	0.133	0.812
Brain_Spinal_cord_cervical_c-1	ENSG00000243753.5	<i>HLA-L</i>	0.016	0.063	0.015	0.059	0.846
Brain_Spinal_cord_cervical_c-1	ENSG00000228022.5	<i>HCG20</i>	2.64e-08	3.28e-06	0.000102	0.012	0.988
Brain_Spinal_cord_cervical_c-1	ENSG00000168631.12	<i>DPCR1</i>	0.002	0.002	0.054	0.07	0.872
Brain_Spinal_cord_cervical_c-1	ENSG00000196260.4	<i>SFTA2</i>	4.26e-11	0.002	1.34e-09	0.059	0.939
Brain_Spinal_cord_cervical_c-1	ENSG00000137310.11	<i>TCF19</i>	1.99e-09	3.82e-09	0.058	0.11	0.832
Brain_Spinal_cord_cervical_c-1	ENSG00000206344.7	<i>HCG27</i>	2.45e-07	3.37e-07	0.056	0.076	0.868
Brain_Spinal_cord_cervical_c-1	ENSG00000204525.16	<i>HLA-C</i>	1.61e-18	1.28e-06	1.29e-13	0.102	0.898
Brain_Spinal_cord_cervical_c-1	ENSG00000204308.7	<i>RNF5</i>	0.004	0.003	0.052	0.043	0.898
Brain_Spinal_cord_cervical_c-1	ENSG00000111816.7	<i>FRK</i>	0.024	0.085	0.005	0.017	0.868
Brain_Spinal_cord_cervical_c-1	ENSG00000231023.6	<i>LINC00326</i>	0.007	0.003	0.06	0.021	0.909
Brain_Spinal_cord_cervical_c-1	ENSG00000247934.4	<i>RP11-967K21.1</i>	0.000392	0.013	0.004	0.117	0.866
Brain_Spinal_cord_cervical_c-1	ENSG00000123427.16	<i>METTL21B</i>	2.7e-14	1.61e-05	1.06e-10	0.062	0.938
Brain_Spinal_cord_cervical_c-1	ENSG00000270039.1	<i>RP11-571M6.17</i>	0.041	0.016	0.058	0.022	0.862
Brain_Spinal_cord_cervical_c-1	ENSG00000073417.14	<i>PDE8A</i>	0.001	0.003	0.032	0.081	0.882
Brain_Spinal_cord_cervical_c-1	ENSG00000183527.11	<i>PSMG1</i>	2.85e-10	0.000245	1.1e-07	0.094	0.905
Brain_Spinal_cord_cervical_c-1	ENSG00000255568.3	<i>BRWD1-AS2</i>	0.000527	0.000327	0.023	0.013	0.963

**Table S8.** Calculated cumulative morbidities and surgery rates for every LSS-associated variant. We also calculated age when the curve of the effect allele (EA) homozygotes statistically differed from the curve of other allele (OA) homozygotes of the same variant (AGE (pval)). Following formula was utilised:  $diff = ('survival rate EA/EA' - 'survival rate OA/OA')/sqrt('se_survival_rate_EA/EA2' + 'se_survival_rate_OA/OA2')$ ,  $p=2*(1-diff)$ .  $P < 0.05$  was used as the threshold for a significant difference. -, no significant difference between the homozygotes.

Candidate Gene	rsid	EA	OA	AGE (pval)	Cum. Morb. EA	Cum. Morb. OA	Cum. Surg. EA	Cum. Surg. OA
<i>RUNX3</i>	rs9438857	G	A	54 ( $p=0.006$ )	6.1%	6.6%	2.7%	3.1%
<i>NGF</i>	rs6327	T	C	54 ( $p=0.005$ )	6.1%	6.7%	2.8%	3.2%
<i>OTUD7B</i>	rs11205303	C	T	40 ( $p=1.82e-06$ )	5.8%	6.6%	2.6%	3.2%
<i>ZNF687</i>	rs147042690	T	C	-	11.6%	6.5%	5.4%	3.1%
<i>PTPRC</i>	rs72739729	C	G	57 ( $p=0.03$ )	5.7%	6.6%	2.6%	3.1%
<i>GFPT1</i>	rs4340572	G	A	44 ( $p=0.0004$ )	6.1%	6.7%	2.8%	3.2%
<i>USP37</i>	rs60362609	G	C	40 ( $p=0.001$ )	6.2%	6.8%	2.9%	3.2%
<i>DAGI</i>	rs138073019	TTTA	T	72 ( $p=0.004$ )	6.4%	6.6%	3.0%	3.1%
<i>RAB28</i>	rs3057070	A	AGAG	61 ( $p=0.01$ )	6.0%	6.6%	2.7%	3.1%
<i>DAB2</i>	rs148346348	ATATG	A	48 ( $p=0.01$ )	7.8%	6.5%	4.0%	3.1%
<i>ITGA2</i>	rs11747379	A	C	52 ( $p=0.049$ )	7.1%	6.5%	3.4%	3.1%
<i>EBF1</i>	rs200608668	G	GC	-	6.9%	6.5%	3.1%	3.1%
<i>BMP6</i>	rs10498672	G	C	55 ( $p=0.0004$ )	7.3%	6.5%	3.8%	3.1%
<i>TRIM38</i>	rs9358913	G	A	61 ( $p=0.02$ )	6.3%	6.6%	2.9%	3.1%
<i>HLA</i>	rs62390186	A	T	-	6.1%	6.6%	2.9%	3.1%
<i>HLA</i>	rs4294047	A	G	-	6.1%	6.6%	2.9%	3.1%
<i>HLA</i>	rs17205170	T	G	54 ( $p=0.02$ )	6.0%	6.6%	2.7%	3.1%
<i>CDC5L</i>	rs7770012	A	C	40 ( $p=1.52e-06$ )	6.8%	6.4%	3.3%	3.0%
<i>LIN28B</i>	rs314261	C	A	50 ( $p=0.03$ )	6.8%	6.4%	3.3%	3.0%
<i>COL10A1</i>	rs7739896	G	A	53 ( $p=0.0003$ )	6.3%	6.6%	2.9%	3.1%
<i>EYA4</i>	rs2764217	A	G	50 ( $p=0.03$ )	7.1%	6.4%	3.3%	3.0%
<i>FOXK1</i>	rs28658109	C	T	46 ( $p=0.02$ )	5.8%	6.6%	2.7%	3.1%
<i>AGMO</i>	rs75674922	G	A	54 ( $p=0.03$ )	7.8%	6.5%	3.8%	3.1%
<i>TWIST1</i>	rs2390116	T	C	62 ( $p=0.02$ )	6.3%	6.6%	2.9%	3.1%
<i>JAZF1</i>	rs849135	A	G	45 ( $p=0.001$ )	6.1%	6.7%	2.8%	3.2%
<i>Empty</i>	rs139203647	G	GT	63 ( $p=0.02$ )	7.7%	6.5%	3.9%	3.1%
<i>DYNCIII</i>	rs11769842	C	T	57 ( $p=0.005$ )	6.8%	6.2%	3.2%	2.9%
<i>MKX</i>	rs2637326	T	G	47 ( $p=0.008$ )	6.8%	6.5%	3.1%	3.1%
<i>MPPED2</i>	rs607165	C	T	55 ( $p=0.001$ )	6.9%	6.4%	3.3%	3.0%
<i>PDE3A</i>	rs73067286	A	T	52 ( $p=0.004$ )	5.8%	6.6%	2.8%	3.1%
<i>SOX5</i>	rs12308843	C	G	40 ( $p=0.0001$ )	7.0%	6.5%	3.4%	3.1%
<i>CCDC91</i>	rs7958415	T	C	46 ( $p=0.005$ )	5.8%	6.6%	2.6%	3.1%
<i>GLI1</i>	rs2069506	A	C	66 ( $p=0.03$ )	6.2%	6.6%	2.9%	3.1%
<i>USP15</i>	rs11174377	A	G	57 ( $p=0.01$ )	7.0%	6.5%	3.3%	3.1%
<i>ZCHC8</i>	rs10846978	C	T	-	6.4%	6.6%	3.1%	3.0%
<i>TNFSF11</i>	rs9594751	T	C	43 ( $p=0.002$ )	5.8%	6.6%	2.5%	3.1%
<i>SLTRK6</i>	rs9531779	G	C	55 ( $p=0.002$ )	6.3%	6.6%	3.0%	3.1%
<i>MMP14</i>	rs1042704	A	G	51 ( $p=0.008$ )	5.9%	6.6%	2.7%	3.1%
<i>GPR132</i>	rs1022431	A	C	-	6.1%	6.6%	2.8%	3.1%
<i>ALDH1A2</i>	rs4646570	C	G	56 ( $p=0.002$ )	7.0%	6.4%	3.5%	3.0%
<i>PPIB</i>	rs148027154	A	T	-	8.1%	6.5%	6.3%	3.1%
<i>SMAD3</i>	rs4776880	A	G	40 ( $p=6.58e-06$ )	6.0%	6.6%	2.8%	3.1%
<i>PDE8A</i>	rs11629962	T	C	54 ( $p=0.01$ )	6.0%	6.6%	2.9%	3.1%
<i>GAN</i>	rs2966084	G	A	56 ( $p=0.01$ )	6.3%	6.8%	3.0%	3.2%
<i>SOCS7</i>	rs113353816	C	T	63 ( $p=0.04$ )	6.7%	6.4%	3.1%	3.0%
<i>AXIN2</i>	rs16961974	C	T	70 ( $p=0.03$ )	6.8%	6.5%	3.2%	3.1%
<i>Empty</i>	rs12941198	C	A	62 ( $p=0.03$ )	6.8%	6.2%	3.2%	2.9%
<i>DCC</i>	rs6508210	C	A	45 ( $p=0.001$ )	6.9%	6.4%	3.2%	3.0%
<i>CACTIN</i>	rs77733715	G	A	-	9.2%	6.5%	4.7%	3.1%
<i>CRLF1</i>	rs2074177	G	A	65 ( $p=0.03$ )	6.0%	6.6%	2.8%	3.1%
<i>DDRGK1</i>	rs11697820	T	C	65 ( $p=0.04$ )	6.3%	6.7%	3.0%	3.1%
<i>ETS2</i>	rs111901809	T	TAGAGGGCAGGGGGCG	47 ( $p=0.004$ )	6.8%	6.4%	3.2%	3.0%
<i>OSM</i>	rs2285645	T	C	-	4.4%	6.6%	2.0%	3.1%

**Table S9.** Genetic correlations between 517 traits and LSS. LDSC-software<sup>95</sup>, was utilised for calculation of the correlations. Traits were extracted from the GWAS database provided by the MRC Integrative Epidemiology Unit (IEU). rg, genetic correlation coefficient value; se, standard error; pFDR, false discovery rate-corrected p-value.

Trait	GWAS-ID	rg	se	pFDR
<b>Diagnoses - main ICD-10: M54 Dorsalgia</b>	ukb-a-569	0.7543	0.06612	7.40e-29
<b>Main ICD-10: M25 Other joint disorders, not elsewhere classified</b>	ukb-d-M25	0.7229	0.1138	1.21e-09
<b>Back pain</b>	ukb-b-9838	0.6031	0.02683	5.05e-109
<b>Leg pain on walking</b>	ukb-b-10387	0.5652	0.04453	1.89e-35
<b>Hip pain</b>	ukb-b-7289	0.5482	0.03365	1.24e-57
<b>Main ICD-10: M70 Soft tissue disorders related to use, overuse, and pressure</b>	ukb-d-M70	0.5014	0.223	0.041
<b>Back pain for 3+ months</b>	ukb-b-8463	0.4958	0.05587	6.79e-18
<b>Main ICD-10: T84 Complications of internal orthopaedic prosthetic devices, implants, and grafts</b>	ukb-d-T84	0.4859	0.08538	5.54e-08
<b>Diagnoses - main ICD-10: J22 Unspecified acute lower respiratory infection</b>	ukb-b-8707	0.4761	0.381	0.278
<b>Diagnoses - main ICD-10: K30 Dyspepsia</b>	ukb-b-14814	0.468	0.1135	0.0001
<b>Number of operations, self-reported</b>	ukb-b-4733	0.458	0.02828	5.38e-57
<b>Neck/shoulder pain for 3+ months</b>	ukb-b-16118	0.4546	0.06353	5.56e-12
<b>Neck or shoulder pain</b>	ukb-b-18596	0.454	0.02897	1.97e-53
<b>Taking other prescription medications</b>	ukb-b-20292	0.4506	0.03005	6.10e-49
<b>Diagnoses - main ICD-10: I20 Angina pectoris</b>	ukb-a-532	0.4443	0.07324	6.50e-09
<b>Diagnoses - main ICD-10: R07 Pain in throat and chest</b>	ukb-a-581	0.4412	0.04621	1.56e-20
<b>Major depressive disorder (ICD-10 coded)</b>	ebi-a-GCST005903	0.4358	0.05246	8.26e-16
<b>Long-standing illness, disability, or infirmity</b>	ukb-b-13764	0.4352	0.02657	3.39e-58
<b>Number of treatments/medications taken</b>	ukb-b-3656	0.4345	0.0243	4.26e-69
<b>Chest pain or discomfort walking normally</b>	ukb-b-11578	0.4327	0.0557	6.08e-14
<b>Had major operations</b>	ukb-b-9937	0.4275	0.05072	3.13e-16
<b>Diagnoses - main ICD-10: J34 Other disorders of nose and nasal sinuses</b>	ukb-a-542	0.4241	0.1592	0.014
<b>Diagnoses - main ICD-10: R11 Nausea and vomiting</b>	ukb-b-19419	0.4234	0.1708	0.023
<b>Pain all over the body</b>	ukb-a-477	0.4129	0.05168	1.08e-14
<b>Diagnoses - main ICD-10: G56 Mononeuropathies of upper limb</b>	ukb-a-528	0.4106	0.05256	4.39e-14
<b>Diagnoses - main ICD-10: R10 Abdominal and pelvic pain</b>	ukb-a-582	0.4106	0.05693	3.85e-12
<b>Why reduced smoking: Illness or ill health</b>	ukb-b-9930	0.4094	0.1838	0.043
<b>Why reduced smoking: Doctor's advice</b>	ukb-b-17579	0.4067	0.2977	0.232
<b>Overall health rating</b>	ukb-b-6306	0.4047	0.02328	2.25e-65
<b>Medication for pain relief, constipation, heartburn: Laxatives</b>	ukb-b-11461	0.4041	0.04579	1.05e-17
<b>Diagnoses - main ICD-10: K29 Gastritis and duodenitis</b>	ukb-a-547	0.4025	0.06778	1.36e-08
<b>Medication for pain relief, constipation, heartburn: Omeprazole</b>	ukb-b-11605	0.3988	0.0431	2.39e-19
<b>Lumbar spine bone mineral density</b>	ieu-a-982	0.3955	0.04694	3.18e-16
<b>Diagnoses - main ICD-10: R35 Polyuria</b>	ukb-b-5948	0.393	0.1248	0.003
<b>Diagnoses - main ICD-10: K52 Other non-infective gastro-enteritis and colitis</b>	ukb-a-554	0.3914	0.09023	4.20e-05
<b>Knee pain</b>	ukb-b-16254	0.384	0.03448	1.40e-27
<b>Diagnoses - main ICD-10: R69 Unknown and unspecified causes of morbidity</b>	ukb-b-12510	0.3832	0.09176	8.24e-05
<b>Knee pain for 3+ months</b>	ukb-b-8906	0.3828	0.08275	1.15e-05
<b>Illness, injury, bereavement, stress in the last 2 years: Serious illness, injury, or assault to yourself</b>	ukb-b-18162	0.3817	0.04249	2.63e-18
<b>Health satisfaction</b>	ukb-b-2053	0.3817	0.03248	1.51e-30
<b>Ever had hysterectomy (womb removed)</b>	ukb-b-6445	0.3769	0.05241	4.32e-12
<b>Diagnoses - main ICD-10: M24 Other specific joint derangements</b>	ukb-a-567	0.3766	0.1149	0.002
<b>Diagnoses - main ICD-10: M21 Other acquired deformities of limbs</b>	ukb-a-565	0.3727	2.404	0.894
<b>Vascular/heart problems diagnosed by doctor: Angina</b>	ukb-b-8468	0.3713	0.03715	2.17e-22
<b>Diagnoses - main ICD-10: M17 Gonarthrosis [arthrosis of knee]</b>	ukb-a-563	0.3702	0.05174	5.56e-12
<b>Had other major operations</b>	ukb-b-15378	0.3677	0.037	3.71e-22
<b>Reason for reducing amount of alcohol drunk: Illness or ill health</b>	ukb-d-2664_1	0.3568	0.1052	0.002
<b>Diagnoses - main ICD-10: G47 Sleep disorders</b>	ukb-a-527	0.3524	0.07514	8.56e-06
<b>Medication for pain relief, constipation, heartburn: Ranitidine</b>	ukb-b-8146	0.3468	0.07108	3.50e-06
<b>Diagnoses - main ICD-10: K62 Other diseases of anus and rectum</b>	ukb-a-557	0.3413	0.08907	0.0003
<b>Ever used hormone-replacement therapy (HRT)</b>	ukb-b-18541	0.3382	0.0357	3.01e-20
<b>Frequency of tiredness/lethargy in last 2 weeks</b>	ukb-b-929	0.3381	0.02681	4.86e-35
<b>Alcohol drinker status: Previous</b>	ukb-a-227	0.3362	0.04852	2.70e-11
<b>Medication for pain relief, constipation, heartburn: Paracetamol</b>	ukb-b-17595	0.3308	0.02845	6.42e-30
<b>Other serious medical condition/disability diagnosed by doctor</b>	ukb-b-14961	0.3305	0.03341	5.74e-22
<b>Ever highly irritable/argumentative for 2 days</b>	ukb-b-8196	0.3302	0.04128	1.01e-14
<b>Shortness of breath walking on level ground</b>	ukb-b-9543	0.3279	0.04709	2.14e-11
<b>Diagnoses - main ICD-10: M16 Coxarthrosis [arthrosis of hip]</b>	ukb-a-562	0.3266	0.0535	5.17e-09
<b>Emphysema/chronic bronchitis</b>	ukb-b-16207	0.325	0.05243	2.97e-09

<b>Diagnoses - main ICD-10: M67 Other disorders of synovium and tendon</b>	ukb-a-570	0.322	0.1519	0.055
<b>Frequency of depressed mood in last 2 weeks</b>	ukb-b-3822	0.3216	0.03533	8.91e-19
<b>Falls in the last year</b>	ukb-b-2535	0.3212	0.03005	1.74e-25
<b>Medication for pain relief, constipation, heartburn: Ibuprofen</b>	ukb-b-8888	0.3184	0.03733	1.35e-16
<b>Childhood asthma (age&lt;16)</b>	ukb-d- ASTHMA CHILD	0.3152	0.08253	0.0003
<b>Diagnoses - main ICD-10: I25 Chronic ischemic heart disease</b>	ukb-a-534	0.3118	0.04279	2.26e-12
<b>Chest pain or discomfort</b>	ukb-b-10591	0.3109	0.02984	2.87e-24
<b>Frequency of unenthusiasm/disinterest in the last 2 weeks</b>	ukb-b-1419	0.3097	0.03351	2.60e-19
<b>Seen doctor (GP) for nerves, anxiety, tension, or depression</b>	ukb-b-6991	0.3076	0.02706	1.12e-28
<b>Diagnoses - main ICD-10: M23 Internal derangement of knee</b>	ukb-a-566	0.3066	0.08106	0.0004
<b>Adopted as a child</b>	ukb-b-13183	0.3047	0.06779	2.11e-05
<b>Diagnoses - main ICD-10: K21 Gastro-oesophageal reflux disease</b>	ukb-a-545	0.3	0.07126	7.16e-05
<b>Transport type for commuting to workplace: Car/motor vehicle</b>	ukb-b-11025	0.2998	0.045	1.66e-10
<b>Frequency of tenseness/restlessness in last 2 weeks</b>	ukb-b-5664	0.2979	0.03016	6.48e-22
<b>Leg fat mass (left)</b>	ukb-b-7212	0.2976	0.02046	3.97e-46
<b>Leg fat mass (right)</b>	ukb-b-18096	0.2957	0.02056	3.96e-45
<b>Coronary artery disease</b>	ebei-a-GCST005195	0.294	0.02842	6.17e-24
<b>Body mass index (BMI)</b>	ukb-b-19953	0.2928	0.01999	9.76e-47
<b>Number of children fathered</b>	ukb-b-2227	0.2927	0.04045	3.24e-12
<b>Bilateral oophorectomy (both ovaries removed)</b>	ukb-a-325	0.2926	0.05574	5.88e-07
<b>Medication for pain relief, constipation, heartburn: Aspirin</b>	ukb-b-7137	0.292	0.034	8.31e-17
<b>Mood swings</b>	ukb-b-14180	0.2895	0.02826	1.67e-23
<b>Wheeze or whistling in the chest in the last year</b>	ukb-b-18335	0.2885	0.03027	1.76e-20
<b>Vascular/heart problems diagnosed by doctor: Heart attack</b>	ukb-b-11590	0.2884	0.04347	1.95e-10
<b>Sleeplessness/insomnia</b>	ukb-b-3957	0.2881	0.02539	1.38e-28
<b>Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Hormone replacement therapy</b>	ukb-b-8080	0.2878	0.0591	3.68e-06
<b>Diagnoses - main ICD-10: Z09 Follow-up examination after treatment for conditions other than malignant neoplasms</b>	ukb-a-594	0.2853	0.1064	0.013
<b>Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Cholesterol lowering medication</b>	ukb-b-17805	0.285	0.03933	3.03e-12
<b>Maternal smoking around birth</b>	ukb-b-17685	0.2835	0.02901	1.79e-21
<b>Noisy workplace</b>	ukb-b-2091	0.2834	0.03983	7.40e-12
<b>Waist circumference</b>	ukb-b-9405	0.2818	0.02043	1.61e-41
<b>Diagnoses - main ICD-10: J44 Other chronic obstructive pulmonary disease</b>	ukb-a-543	0.279	0.09043	0.0039943
<b>Former alcohol drinker</b>	ukb-b-12654	0.279	0.05559	1.82e-06
<b>Diagnoses - main ICD-10: J45.9 Asthma, unspecified</b>	ukb-b-20208	0.2786	0.1467	0.087
<b>Ever had bowel cancer screening</b>	ukb-b-17001	0.2772	0.04815	3.83e-08
<b>Vitamin and mineral supplements: Vitamin B</b>	ukb-b-10188	0.2771	0.05369	9.11e-07
<b>Diagnoses - main ICD-10: K20 Oesophagitis</b>	ukb-b-19354	0.2766	0.09267	0.005
<b>Weight</b>	ukb-b-11842	0.2762	0.02042	4.90e-40
<b>Main ICD-10: N92 Excessive , frequent, and irregular menstruation</b>	ukb-d-N92	0.2752	0.06264	3.30e-05
<b>Operation code: bilateral oophorectomy</b>	ukb-b-1962	0.2741	0.05391	1.34e-06
<b>Arm fat-free mass (left)</b>	ukb-b-19925	0.2726	0.02016	4.90e-40
<b>Bring up phlegm/sputum/mucus on most days</b>	ukb-b-12841	0.2719	0.06711	0.0001
<b>Arm fat-free mass (right)</b>	ukb-b-19520	0.2711	0.0199	1.39e-40
<b>Major coronary heart disease event</b>	ukb-d-19 CHD	0.268	0.04379	4.77e-09
<b>Leg fat percentage</b>	ukb-b-18377	0.2678	0.02094	6.06e-36
<b>Arm fat mass (right)</b>	ukb-b-6704	0.2678	0.02024	1.91e-38
<b>Arm fat mass (left)</b>	ukb-b-8338	0.2676	0.0205	2.14e-37
<b>Depressive symptoms</b>	ieu-a-1000	0.2674	0.04703	5.68e-08
<b>Fed-up feelings</b>	ukb-b-19809	0.2673	0.02992	4.03e-18
<b>Blood clot in the lung</b>	ukb-b-13704	0.2668	0.0736	0.0006
<b>Stomach or abdominal pain</b>	ukb-b-11413	0.2667	0.04577	2.56e-08
<b>Diagnoses - main ICD-10: R04 Haemorrhage from respiratory passages</b>	ukb-a-580	0.2656	0.1251	0.054
<b>Whole body fat mass</b>	ukb-b-19393	0.2642	0.02067	6.47e-36
<b>Smoking status: Current</b>	ukb-a-225	0.2626	0.03102	2.25e-16
<b>Diagnoses - secondary ICD-10: M06.99 Rheumatoid arthritis, unspecified (Site unspecified)</b>	ukb-b-11874	0.2622	0.08531	0.004
<b>Diagnoses - main ICD-10: K43 Ventral hernia</b>	ukb-a-550	0.2605	0.07408	0.001
<b>Leg fat percentage (right)</b>	ukb-b-20531	0.2592	0.02091	7.00e-34
<b>Pack years of smoking</b>	ukb-b-10831	0.2577	0.03279	3.03e-14
<b>Pulse wave arterial stiffness index</b>	ukb-b-11971	0.2573	0.04611	1.00e-07
<b>Ever stopped smoking for 6+ months</b>	ukb-b-11355	0.2542	0.08089	0.003
<b>Hip circumference</b>	ukb-b-15590	0.2531	0.01998	2.49e-35
<b>Smoking/smokers in household</b>	ukb-b-960	0.253	0.04618	1.77e-07
<b>Qualifications: None of the above</b>	ukb-b-17729	0.2525	0.02252	6.24e-28
<b>Basal metabolic rate</b>	ukb-b-16446	0.2518	0.02022	3.54e-34

<b>Loneliness, isolation</b>	ukb-b-8476	0.25	0.03266	1.46e-13
<b>Other eye problems</b>	ukb-b-7007	0.2495	0.04843	9.49e-07
<b>Illness, injury, bereavement, stress in the last 2 years: Financial difficulties</b>	ukb-b-9667	0.2484	0.03138	1.94e-14
<b>Ever had stillbirth, spontaneous miscarriage, or termination</b>	ukb-b-12621	0.2474	0.04761	7.63e-07
<b>Smoking initiation</b>	ieu-b-4877	0.2471	0.0211	2.31e-30
<b>Type 2 diabetes</b>	ebi-a-GCST006867	0.2469	0.02953	5.53e-16
<b>Mouth/teeth dental problems: Toothache</b>	ukb-b-19191	0.2447	0.06593	0.0005
<b>Job involves shift work</b>	ukb-b-1712	0.2445	0.04163	1.99e-08
<b>Blood clot in the leg (DVT)</b>	ukb-b-11411	0.2417	0.0562	4.87e-05
<b>Trunk fat mass</b>	ukb-b-20044	0.2414	0.02109	4.79e-29
<b>Reason for reducing amount of alcohol drunk: Doctor's advice</b>	ukb-d-2664 2	0.2413	0.1144	0.056
<b>Job involves heavy manual or physical work</b>	ukb-b-2002	0.2395	0.02884	8.26e-16
<b>Whole body water mass</b>	ukb-b-14540	0.2394	0.02025	6.92e-31
<b>Diagnoses - main ICD-10: K22 Other diseases of oesophagus</b>	ukb-a-546	0.2383	0.09374	0.019
<b>Whole body fat-free mass</b>	ukb-b-13354	0.2375	0.02024	1.87e-30
<b>Current tobacco smoking</b>	ukb-b-223	0.2367	0.02884	1.84e-15
<b>Childhood obesity</b>	ieu-a-1096	0.2352	0.04796	3.13e-06
<b>Leg fat free-mass (left)</b>	ukb-b-16099	0.2337	0.0206	1.42e-28
<b>Facial pain</b>	ukb-b-17107	0.2337	0.07309	0.003
<b>Diagnoses - main ICD-10: I10 Essential (primary) hypertension</b>	ukb-a-531	0.2335	0.1284	0.102
<b>Diabetes diagnosed by doctor</b>	ukb-b-10753	0.2332	0.03192	2.01e-12
<b>Financial situation satisfaction</b>	ukb-b-2830	0.2328	0.03736	2.47e-09
<b>Extreme waist-to-hip ratio</b>	ieu-a-87	0.2324	0.07126	0.002
<b>Seen a psychiatrist for nerves, anxiety, tension, or depression</b>	ukb-b-18336	0.2322	0.0354	3.15e-10
<b>Average weekly spirits intake</b>	ukb-b-1707	0.2321	0.03499	1.99e-10
<b>Qualifications: NVQ or HND or HNC or equivalent</b>	ukb-b-7926	0.2303	0.03987	3.45e-08
<b>Leg fat-free mass (right)</b>	ukb-b-12828	0.2279	0.02049	1.65e-27
<b>Waist-to-hip ratio</b>	ieu-a-72	0.2278	0.03047	5.64e-13
<b>Diagnoses - main ICD-10: I21 Acute myocardial infarction</b>	ukb-a-533	0.2274	0.06478	0.001
<b>Miserableness</b>	ukb-b-18994	0.227	0.03078	1.20e-12
<b>Trunk fat-free mass</b>	ukb-b-17409	0.2257	0.02043	3.61e-27
<b>Body fat percentage</b>	ukb-b-8909	0.2227	0.02107	5.84e-25
<b>Number of full brothers</b>	ukb-b-4263	0.222	0.04402	1.64e-06
<b>Number of older siblings</b>	ukb-b-1997	0.2196	0.07887	0.010
<b>Vascular/heart problems diagnosed by doctor: Stroke</b>	ukb-b-8714	0.2194	0.07199	0.005
<b>Arm fat percentage (left)</b>	ukb-b-20188	0.2191	0.02083	9.77e-25
<b>Arm fat percentage (right)</b>	ukb-b-12854	0.2182	0.0207	7.95e-25
<b>Ever unenthusiastic/disinterested for a whole week</b>	ukb-b-18674	0.2181	0.03865	7.22e-08
<b>Types of physical activity in last 4 weeks: None of the above</b>	ukb-b-15869	0.2177	0.03735	2.56e-08
<b>Vascular/heart problems diagnosed by doctor: High blood pressure</b>	ukb-b-14177	0.2174	0.02334	1.36e-19
<b>Mouth/teeth dental problems: Dentures</b>	ukb-b-12930	0.2173	0.03016	4.02e-12
<b>Mouth/teeth dental problems: Painful gums</b>	ukb-b-11161	0.217	0.05991	0.0007
<b>Diagnoses - main ICD-10: M20 Acquired deformities of fingers and toes</b>	ukb-a-564	0.2157	0.05354	0.0001
<b>Vitamin and mineral supplements: Vitamin A</b>	ukb-b-9596	0.2145	0.08409	0.019
<b>Diagnoses - main ICD-10: K44 Diaphragmatic hernia</b>	ukb-a-551	0.214	0.07704	0.010
<b>Diagnoses - main ICD-10: R31 Unspecified haematuria</b>	ukb-b-17885	0.2136	0.07223	0.006
<b>Cigarettes smoked per day</b>	ieu-b-142	0.2133	0.03089	3.14e-11
<b>Cigarettes per day</b>	ieu-b-25	0.2133	0.03089	3.14e-11
<b>Diagnoses - main ICD-10: I84 Haemorrhoids</b>	ukb-a-539	0.2131	0.05595	0.0003
<b>Exposure to tobacco smoke at home</b>	ukb-b-4462	0.2103	0.04221	2.15e-06
<b>Qualifications: CSEs or equivalent</b>	ukb-b-10505	0.2067	0.03774	1.79e-07
<b>Mineral and other dietary supplements: Glucosamine</b>	ukb-b-11535	0.2055	0.03419	9.13e-09
<b>Tinnitus, Yes, but not now, but have in the past</b>	ukb-d-4803 14	0.2052	0.06871	0.005
<b>Number of cigarettes previously smoked daily</b>	ukb-b-6019	0.2036	0.03921	7.72e-07
<b>Neuroticism score</b>	ukb-b-4630	0.2006	0.03033	2.24e-10
<b>Time spent watching television</b>	ukb-b-5192	0.1964	0.0236	7.45e-16
<b>Trunk fat percentage</b>	ukb-b-16407	0.196	0.02144	6.49e-19
<b>Handedness (chirality/laterality): Use both right and left hands equally</b>	ukb-a-37	0.1957	0.09527	0.063
<b>Frequency of heavy DIY in last 4 weeks</b>	ukb-b-5053	0.1954	0.05564	0.001
<b>Fractured bone site(s): Spine</b>	ukb-b-873	0.1952	0.1851	0.361
<b>Diagnoses - main ICD-10: N40 Hyperplasia of prostate</b>	ukb-b-11601	0.1951	0.06251	0.004
<b>Duration of heavy DIY</b>	ukb-b-2634	0.1947	0.04471	3.90e-05
<b>Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Blood pressure medication</b>	ukb-b-18009	0.1943	0.028	2.51e-11
<b>Diagnoses - main ICD-10: K60 Fissure and fistula of anal and rectal regions</b>	ukb-a-556	0.1928	0.08046	0.028
<b>Light smokers, at least 100 smokes in lifetime</b>	ukb-b-8133	0.1926	0.03768	1.16e-06
<b>Neuroticism</b>	ebi-a-GCST005232	0.1912	0.03064	2.36e-09
<b>Job involves mainly walking or standing</b>	ukb-b-4461	0.1886	0.02835	1.77e-10

<b>Eye problems/disorders: Injury or trauma resulting in loss of vision</b>	ukb-b-9050	0.1877	0.1193	0.163
<b>Diagnoses - main ICD-10: N81 Female genital prolapse</b>	ukb-a-577	0.1876	0.06647	0.009
<b>HOMA-IR</b>	ieu-b-118	0.1872	0.07464	0.021
<b>Eye problems/disorders: Diabetes related eye disease</b>	ukb-b-10181	0.1868	0.06675	0.010
<b>Ever manic/hyper for 2 days</b>	ukb-b-15272	0.1843	0.05674	0.002
<b>Tense/'highly strung'</b>	ukb-b-10093	0.1842	0.0309	1.21e-08
<b>Cataract</b>	bbj-a-94	0.1822	0.08889	0.063
<b>Illness, injury, bereavement, stress in the last 2 years: Marital separation/divorce</b>	ukb-b-14624	0.181	0.0859	0.056
<b>Vitamin and mineral supplements: Vitamin E</b>	ukb-b-12506	0.1799	0.06726	0.014
<b>Fractured bone site(s): Other bones</b>	ukb-b-17738	0.1795	0.05673	0.003
<b>Diagnoses - main ICD-10: S76 Injury of muscle and tendon at hip and thigh level</b>	ukb-a-592	0.1791	0.1568	0.321
<b>Fractured bone site(s): Ankle</b>	ukb-b-15582	0.1766	0.07074	0.022
<b>Triglycerides</b>	ieu-b-111	0.1758	0.02727	6.61e-10
<b>Hearing difficulty/problems: Yes</b>	ukb-a-257	0.1754	0.03368	7.23e-07
<b>Diagnoses - main ICD-10: K80 Cholelithiasis</b>	ukb-a-559	0.171	0.06786	0.020
<b>Smoking status: Previous</b>	ukb-a-224	0.1702	0.03021	7.61e-08
<b>Diagnoses - main ICD-10: K57 Diverticular disease of intestine</b>	ukb-a-555	0.17	0.05136	0.002
<b>Headache</b>	ukb-b-12181	0.1688	0.03406	2.45e-06
<b>Diagnoses - main ICD-10: K76 Other diseases of liver</b>	ukb-a-558	0.168	0.09632	0.118
<b>Irritability</b>	ukb-b-13745	0.1665	0.03492	6.00e-06
<b>Alcohol intake versus 10 years previously</b>	ukb-b-3460	0.1647	0.032	9.70e-07
<b>Number of full sisters</b>	ukb-b-5593	0.1629	0.04458	0.0006
<b>Duration of moderate activity</b>	ukb-b-2346	0.1609	0.03531	1.60e-05
<b>Illness, injury, bereavement, stress in the last 2 years: Death of a close relative</b>	ukb-b-18712	0.1581	0.05821	0.012
<b>Types of transport used (excluding work): None of the above</b>	ukb-b-12386	0.1556	0.1264	0.286
<b>Prospective memory result</b>	ukb-b-4282	0.1544	0.03804	0.0001
<b>Tinnitus, Yes, now a lot of the time</b>	ukb-d-4803_12	0.154	0.1353	0.322
<b>Risk taking</b>	ukb-b-14147	0.1538	0.0283	2.21e-07
<b>Diagnoses - main ICD-10: I30 Acute pericarditis</b>	ukb-a-535	0.1515	0.1111	0.233
<b>Pulse wave reflection index</b>	ukb-b-11598	0.1515	0.04294	0.0009
<b>Ever smoked</b>	ukb-b-20261	0.1515	0.02426	2.32e-09
<b>Diagnoses - main ICD-10: J33 Nasal polyp</b>	ukb-a-541	0.1493	0.1045	0.211
<b>Exposure to tobacco smoke outside home</b>	ukb-b-6244	0.1492	0.03656	0.0001
<b>Ever depressed for a whole week</b>	ukb-b-6848	0.1484	0.04074	0.0006
<b>Cough on most days</b>	ukb-b-16858	0.1483	0.05386	0.011
<b>Diagnoses - main ICD-10: R55 Syncope and collapse</b>	ukb-b-16187	0.148	0.0645	0.036
<b>Time spent driving</b>	ukb-b-3793	0.1459	0.03543	0.0001
<b>Suffer from 'nerves'</b>	ukb-b-19957	0.1453	0.03408	5.66e-05
<b>Length of working week for main job</b>	ukb-b-8013	0.1435	0.04645	0.004
<b>Duration of vigorous activity</b>	ukb-b-13932	0.1426	0.0408	0.001
<b>Alcohol intake frequency</b>	ukb-b-5779	0.1426	0.02293	2.62e-09
<b>Number of live births</b>	ukb-b-1209	0.1425	0.02977	5.50e-06
<b>Frequency of walking for pleasure in last 4 weeks</b>	ukb-b-4655	0.1412	0.03298	5.30e-05
<b>Diagnoses - main ICD-10: M10 Gout</b>	ukb-a-561	0.1407	0.111	0.272
<b>Fractured/broken bones in the last 5 years</b>	ukb-b-13346	0.138	0.03926	0.001
<b>Comparative body size at age 10</b>	ukb-b-4650	0.1374	0.02317	1.43e-08
<b>Sensitivity/hurt feelings</b>	ukb-b-9981	0.1371	0.02911	7.85e-06
<b>Hearing difficulty/problems with background noise</b>	ukb-b-18275	0.1368	0.0274	2.04e-06
<b>Duration of walks</b>	ukb-b-16998	0.1361	0.02992	1.65e-05
<b>Vitamin and mineral supplements: Folic acid or Folate (Vitamin B9)</b>	ukb-b-3563	0.1344	0.09683	0.224
<b>HOMA-B</b>	ieu-b-117	0.1339	0.06558	0.064
<b>Ischemic stroke</b>	ebi-a-GCST005843	0.1334	0.04006	0.002
<b>Tinnitus, Yes, now some of the time</b>	ukb-d-4803_13	0.1334	0.08961	0.190
<b>Hearing aid user</b>	ukb-b-19060	0.1302	0.04883	0.014
<b>Ever had prostate specific antigen (PSA) test</b>	ukb-b-15695	0.128	0.0387	0.002
<b>Average weekly intake of other alcoholic drinks</b>	ukb-b-3831	0.1275	0.2105	0.612
<b>Diagnoses - main ICD-10: S66 Injury of muscle and tendon at wrist and hand level</b>	ukb-a-591	0.1273	0.09657	0.252
<b>Duration of light DIY</b>	ukb-b-2993	0.1268	0.03888	0.002
<b>Sodium in urine</b>	ukb-b-335	0.1252	0.02768	1.86e-05
<b>Mouth/teeth dental problems: Loose teeth</b>	ukb-b-12849	0.1243	0.04745	0.016
<b>Townsend deprivation index at recruitment</b>	ukb-b-10011	0.1235	0.03261	0.0004
<b>Squamous cell lung cancer</b>	ieu-a-967	0.1202	0.1038	0.314
<b>Weight change compared with 1 year ago</b>	ukb-b-2094	0.1202	0.04725	0.019
<b>Diagnoses - main ICD-10: N32 Other disorders of bladder</b>	ukb-a-575	0.1198	0.08434	0.213
<b>Fractured bone site(s): Leg</b>	ukb-b-3798	0.1194	0.1347	0.448
<b>Creatinine (enzymatic) in the urine</b>	ukb-a-333	0.1178	0.02655	2.72e-05
<b>Chronic kidney disease</b>	ieu-a-1102	0.1174	0.07639	0.175
<b>Diagnoses - main ICD-10: I80 Phlebitis and thrombophlebitis</b>	ukb-a-537	0.1137	0.06562	0.121

<b>Number of children ever born measurement</b>	ieu-b-4828	0.1126	0.06696	0.134
Used an inhaler for chest within last hour	ukb-b-11188	0.1112	0.09264	0.298
<b>Forearm bone mineral density</b>	ieu-a-977	0.1098	0.1023	0.352
Illness, injury, bereavement, stress in the last 2 years: Serious illness, injury, or assault of a close relative	ukb-b-9049	0.108	0.05784	0.093
Daytime dozing/sleeping (narcolepsy)	ukb-b-5776	0.1071	0.02811	0.0003
Tinnitus, Yes, now most or all the time	ukb-d-4803_11	0.1071	0.05537	0.081
<b>Heel bone mineral density (BMD) T-score, automated</b>	ukb-b-20124	0.104	0.02594	0.0002
Doctor diagnosed hayfever or allergic rhinitis	ukb-b-7178	0.1033	0.03617	0.008
<b>Guilty feelings</b>	ukb-b-10169	0.1031	0.03145	0.002
Why reduced smoking: None of the above	ukb-b-19752	0.1028	0.2225	0.700
Mineral and other dietary supplements: Fish oil (including cod liver oil)	ukb-b-11075	0.1024	0.0325	0.003
<b>Types of transport used (excluding work): Car/motor vehicle</b>	ukb-b-16886	0.1007	0.03278	0.004
Lung adenocarcinoma	ieu-a-965	0.1002	0.1299	0.512
<b>Diagnoses - main ICD-10: S09 Other and unspecified injuries of head</b>	ukb-a-589	0.09838	0.08634	0.322
Ever taken oral contraceptive pill	ukb-b-9509	0.09814	0.04513	0.049
Cancer diagnosed by doctor	ukb-b-16855	0.09713	0.05768	0.133
Worrier/anxious feelings	ukb-b-6519	0.09618	0.0298	0.003
Headaches for 3+ months	ukb-b-13092	0.09525	0.04212	0.039
Non-accidental death in close genetic family	ukb-b-19722	0.09376	0.06716	0.222
Diastolic blood pressure, automated reading	ukb-b-7992	0.09332	0.02266	0.0001
Mineral and other dietary supplements: Zinc	ukb-b-13891	0.09248	0.04737	0.078
<b>Duration of strenuous sports</b>	ukb-b-1046	0.08947	0.08951	0.390
Vitamin and mineral supplements: Multivitamins +/- minerals	ukb-b-16812	0.08725	0.03723	0.032
Frequency of travelling from home to workplace	ukb-b-185	0.08528	0.04487	0.087
Number of cigarettes currently smoked daily (current cigarette smokers)	ukb-b-469	0.08419	0.05766	0.199
Sitting height ratio	ieu-a-1070	0.0792	0.04958	0.156
<b>Diagnoses - main ICD-10: E04 Other non-toxic goitre</b>	ukb-a-524	0.07919	0.07815	0.382
Comparative height size at age 10	ukb-a-35	0.07918	0.02399	0.002
Femoral neck bone mineral density	ieu-a-980	0.07917	0.04109	0.083
Systemic lupus erythematosus	ebi-a-GCST003156	0.07866	0.05133	0.176
<b>Diagnoses - main ICD-10: I48 Atrial fibrillation and flutter</b>	ukb-b-964	0.07756	0.04915	0.161
<b>Diagnoses - main ICD-10: L03 Cellulitis</b>	ukb-a-560	0.07584	0.09574	0.499
Sitting height	ukb-b-16881	0.07438	0.02223	0.002
Reason for reducing amount of alcohol drunk: Financial reasons	ukb-d-2664_4	0.07341	0.08587	0.464
Nap during day	ukb-b-4616	0.07316	0.02342	0.004
Eye problems/disorders: Cataract	ukb-b-8329	0.07225	0.05873	0.286
Loud music exposure frequency	ukb-b-5436	0.06994	0.0469	0.190
Mineral and other dietary supplements: Selenium	ukb-b-19158	0.06769	0.0702	0.409
Systolic blood pressure, automated reading	ukb-b-20175	0.06732	0.02413	0.010
Duration of other exercises	ukb-b-4512	0.06716	0.0567	0.304
Multiple sclerosis	ieu-b-18	0.06693	0.03586	0.093
Handedness (chirality/laterality): Right-handed	ukb-d-1707_1	0.06594	0.05767	0.321
Extreme height	ieu-a-86	0.06538	0.03967	0.142
Pulse rate, automated reading	ukb-b-18103	0.06127	0.02302	0.014
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Insulin	ukb-b-14070	0.06009	0.08896	0.569
Vitamin and mineral supplements: Vitamin C	ukb-b-15175	0.06003	0.05097	0.307
Had menopause	ukb-b-18105	0.05961	0.04721	0.272
Urinary albumin-to-creatinine ratio	ieu-a-1107	0.05954	0.07012	0.466
Serum creatinine	bbj-a-61	0.05629	0.03415	0.142
Wears glasses or contact lenses	ukb-b-14576	0.05596	0.04624	0.294
Primary biliary cirrhosis	ebi-a-GCST005581	0.05485	0.09256	0.621
Average weekly beer plus cider intake	ukb-b-5174	0.05434	0.03398	0.156
<b>Diagnoses - main ICD-10: H26 Other cataract</b>	ukb-a-530	0.05375	0.06039	0.448
<b>Diagnoses - main ICD-10: N20 Calculus of kidney and ureter</b>	ukb-a-574	0.05303	0.07094	0.525
<b>Diagnoses - main ICD-10: I83 Varicose veins of lower extremities</b>	ukb-a-538	0.05231	0.04598	0.322
Reason for glasses/contact lenses: For a 'lazy' eye or an eye with poor vision since childhood (called 'amblyopia')	ukb-b-9139	0.05117	0.08338	0.607
Circulating leptin levels	ebi-a-GCST003367	0.05094	0.05746	0.448
Type of tobacco previously smoked: Manufactured cigarettes	ukb-d-2877_1	0.0508	0.07762	0.581
Vitamin and mineral supplements: Vitamin D	ukb-b-12648	0.04979	0.06548	0.518
Bipolar disorder	ieu-b-41	0.04951	0.02938	0.133
C-reactive protein	bbj-a-14	0.04877	0.09683	0.674
Distance between home and workplace	ukb-b-20455	0.04753	0.06883	0.560
Platelet count	ukb-d-30080_irnt	0.0472	0.02128	0.044
Offspring birth weight	ebi-a-GCST005314	0.04685	0.04316	0.346
<b>Diagnoses - main ICD-10: H26.9 Cataract, unspecified</b>	ukb-b-12397	0.04672	0.05476	0.464
Cerebral aneurysm	bbj-a-96	0.04643	0.05856	0.499
Difference in height between childhood and adulthood	ieu-a-1037	0.04638	0.06269	0.529

HbA1c	ieu-b-4842	0.04572	0.04479	0.378
Mouth/teeth dental problems: Mouth ulcers	ukb-b-6458	0.04534	0.03238	0.220
Main ICD-10: D12 Benign neoplasm of colon, rectum, anus, and anal canal	ukb-d-D12	0.04429	0.05291	0.473
Number of unsuccessful stop-smoking attempts	ukb-b-4801	0.04343	0.04976	0.456
Diagnoses - main ICD-10: H25 Senile cataract	ukb-a-529	0.04242	0.1048	0.731
Diagnoses - main ICD-10: K50 Crohn's disease [regional enteritis]	ukb-a-552	0.04179	0.08783	0.693
Platelet crit	ukb-d-30090 irnt	0.04057	0.02228	0.101
Family relationship satisfaction	ukb-b-3666	0.04006	0.03337	0.297
Diagnoses - main ICD-10: D25 Leiomyoma of uterus	ukb-a-522	0.03965	0.06031	0.579
Forced expiratory volume in 1-second (FEV1) , predicted	ukb-b-8428	0.03778	0.03093	0.289
Nervous feelings	ukb-b-20544	0.0364	0.03145	0.314
Number of days/week of moderate physical activity 10+ minutes	ukb-b-4710	0.03618	0.03084	0.308
Number of incorrect matches in round	ukb-b-20498	0.03595	0.02599	0.226
Diagnoses - main ICD-10: C61 Malignant neoplasm of prostate	ukb-b-2160	0.03195	0.076	0.722
Work/job satisfaction	ukb-b-2105	0.03118	0.04671	0.574
Inflammatory bowel disease	ebi-a-GCST004131	0.03061	0.03342	0.436
Lung function (FEV1/FVC)	ebi-a-GCST007431	0.02682	0.02254	0.302
Transferrin	ieu-a-1052	0.02659	0.07843	0.781
Alcohol drinker status: Never	ukb-a-226	0.02626	0.04579	0.631
Ferritin levels	ebi-a-GCST005072	0.02617	0.06198	0.722
Number of pregnancy terminations	ukb-b-4958	0.02551	0.04773	0.657
Systolic blood pressure	ieu-b-38	0.02419	0.02088	0.314
Frequency of other exercises in last 4 weeks	ukb-b-3502	0.02272	0.0467	0.687
Reason for glasses/contact lenses: For a 'squint' or 'turn' in an eye since childhood (called 'strabismus')	ukb-b-11465	0.02246	0.07296	0.799
Uric acid	bbj-a-57	0.0221	0.02761	0.496
Potassium in urine	ukb-a-334	0.02044	0.03224	0.594
Fractured bone site(s): Wrist	ukb-b-9571	0.0188	0.06779	0.817
Diastolic blood pressure	ieu-b-39	0.01799	0.02164	0.477
Number of days/weeks of vigorous physical activity 10+ minutes	ukb-b-151	0.01773	0.02777	0.592
Hand grip strength	ukb-b-7478	0.01671	0.02272	0.531
Standing height	ukb-b-10787	0.01637	0.02086	0.503
Happiness	ukb-b-4062	0.01437	0.03424	0.722
Diagnoses - main ICD-10: K51 Ulcerative colitis	ukb-a-553	0.01424	0.07698	0.877
Reason for glasses/contact lenses: For long-sightedness (called 'hypermetropia')	ukb-b-18189	0.01392	0.06018	0.849
Eczema	ieu-a-996	0.01207	0.06553	0.877
Type of tobacco previously smoked: Hand-rolled cigarettes	ukb-d-2877_2	0.01138	0.1056	0.926
Diagnoses - main ICD-10: K40 Inguinal hernia	ukb-a-549	0.01124	0.05112	0.854
Reason for reducing amount of alcohol drunk: Other reason	ukb-d-2664_5	0.009846	0.04397	0.852
Diagnoses - main ICD-10: M72 Fibroblastic disorders	ukb-a-572	0.007981	0.05224	0.894
Underlying (primary) cause of death: ICD-10 C34.9 Bronchus or lung, unspecified	ukb-d-40001_C349	0.007745	0.1028	0.950
Worry too long after embarrassment	ukb-b-13653	0.007505	0.0289	0.829
Total cholesterol	ieu-a-301	0.006143	0.03893	0.893
Diagnoses - main ICD-10: Z47 Other orthopaedic follow-up care	ukb-a-595	0.005589	0.08483	0.952
Peak expiratory flow (PEF)	ukb-b-12019	0.005417	0.02583	0.860
Apolipoprotein B	ieu-b-108	0.004527	0.02631	0.885
Hand grip strength (right)	ukb-b-10215	0.004473	0.02308	0.871
Amyotrophic lateral sclerosis	ebi-a-GCST005647	0.002829	0.06731	0.969
Frequency of light DIY in last 4 weeks	ukb-b-4210	0.002088	0.04373	0.966
Difference in height between adolescence and adulthood	ieu-a-1040	0.001982	0.06836	0.978
Number of depression episodes	ukb-b-1464	-0.00611	0.08342	0.950
Platelet distribution width	ukb-d-30110_irnt	-0.00867	0.02691	0.792
Alzheimer's disease	ieu-b-2	-0.01049	0.06436	0.891
Birth weight	ukb-b-13378	-0.01258	0.02386	0.659
Mineral and other dietary supplements: Calcium	ukb-b-7043	-0.0161	0.0504	0.792
Diagnoses - main ICD-10: E03 Other hyperthyroidism	ukb-a-523	-0.01671	0.2381	0.950
Diagnoses - main ICD-10: C50 Malignant neoplasm of breast	ukb-a-519	-0.01701	0.05611	0.801
Reproducibility of spirometry measurement using ERS/ATS criteria	ukb-b-19066	-0.01711	0.05166	0.786
Friendship satisfaction	ukb-b-3304	-0.01741	0.03693	0.694
Mean platelet volume	ebi-a-GCST004599	-0.01764	0.02027	0.456
Number of days/week walked 10+ minutes	ukb-b-4886	-0.01806	0.03092	0.624
Glaucoma	bbj-a-121	-0.01828	0.06901	0.826
Schizophrenia	ieu-a-22	-0.02027	0.02541	0.497
Diagnoses - main ICD-10: F43 Reaction to severe stress and adjustments disorders	ukb-a-526	-0.02277	0.201	0.923
Birth weight of first child	ukb-b-3357	-0.02364	0.02856	0.478
Diagnoses - main ICD-10: N19 Unspecified renal failure	ukb-a-573	-0.02447	0.1021	0.843
Diagnoses -main ICD-10: C44 Other malignant neoplasm of skin	ukb-a-518	-0.02504	0.05774	0.717
Mean platelet (thrombocyte) volume	ukb-d-30100_irnt	-0.02601	0.01979	0.253

<b>Infant head circumference</b>	ieu-a-28	-0.02848	0.06305	0.706
Pallidum volume	ieu-a-1046	-0.02874	0.06629	0.717
Ferritin	ieu-a-1050	-0.02992	0.08485	0.772
<b>Forced expiratory volume 1-second (FEV1), Best measure</b>	ukb-b-11141	-0.03696	0.02462	0.186
<b>Time spent using computer</b>	ukb-b-4522	-0.04105	0.02322	0.113
<b>Forced expiratory volume in 1-second (FEV1)</b>	ukb-b-19657	-0.0428	0.02356	0.102
<b>Getting up in the morning</b>	ukb-b-2772	-0.04464	0.02434	0.099
<b>Neo-consciousness</b>	ieu-a-114	-0.04494	0.1065	0.722
<b>Mouth/teeth dental problems: Bleeding gums</b>	ukb-b-7872	-0.04589	0.0336	0.232
<b>Type of tobacco previously smoked: Cigars and pipes</b>	ukb-a-327	-0.0459	0.09557	0.690
<b>Forced vital capacity (FVC), Best measure</b>	ukb-b-14713	-0.04689	0.02442	0.084
<b>LDL cholesterol</b>	ieu-b-110	-0.04904	0.02707	0.103
<b>Nucleus accumbens volume</b>	ieu-a-1042	-0.04971	0.1114	0.709
<b>Forced vital capacity (FVC)</b>	ukb-b-7953	-0.05151	0.02353	0.047
<b>Mineral and other dietary supplements: Iron</b>	ukb-b-14863	-0.05167	0.06936	0.526
<b>Autism spectrum disorder</b>	ieu-a-1185	-0.05266	0.04111	0.266
<b>Fractured bone site(s): Arm</b>	ukb-b-19255	-0.05672	0.105	0.654
<b>Morning/evening person (chronotype)</b>	ukb-b-4956	-0.05691	0.02258	0.020
<b>Diagnoses - main ICD-10: K35 Acute appendicitis</b>	ukb-a-548	-0.05788	0.1269	0.703
<b>Subjective well being</b>	ieu-a-1009	-0.06181	0.04731	0.256
<b>Forced expiratory volume 1-second (FEV1), predicted percentage</b>	ukb-b-13405	-0.06315	0.02909	0.049
<b>Putamen volume</b>	ieu-a-1047	-0.06383	0.05789	0.338
<b>Parkinson's disease</b>	ieu-b-7	-0.06416	0.04234	0.182
<b>Thalamus volume</b>	ieu-a-1048	-0.06972	0.07702	0.441
<b>Anorexia nervosa</b>	ieu-a-1186	-0.07211	0.05064	0.212
<b>Caudate volume</b>	ieu-a-1044	-0.07359	0.0623	0.306
<b>Reason for glasses/contact lenses: For just reading/near work as you are getting old (called 'presbyopia')</b>	ukb-b-16235	-0.07856	0.09162	0.463
<b>Age at menarche</b>	ieu-b-4822	-0.08198	0.04917	0.137
<b>Mean time to correctly identify matches</b>	ukb-b-16287	-0.08454	0.02531	0.002
<b>Fracture resulting from simple fall</b>	ukb-b-15251	-0.08524	0.06992	0.290
<b>Length of menstrual cycle</b>	ukb-b-3278	-0.09299	0.04312	0.050
<b>Diagnoses - main ICD-10: O75 Other complications of labour and delivery not elsewhere classified</b>	ukb-a-579	-0.09448	0.09706	0.405
<b>Vitamin and mineral supplements: None of the above</b>	ukb-b-17381	-0.09521	0.03501	0.012
<b>Relative age of first facial hair</b>	ukb-b-5945	-0.09538	0.02687	0.0009
<b>Fasting blood glucose adjusted for BMI</b>	ebi-a-GCST007858	-0.09635	0.1085	0.448
<b>Mineral and other dietary supplements: None of the above</b>	ukb-b-14238	-0.1002	0.03205	0.004
<b>Diagnoses - main ICD-10: Z80 Family history of malignant neoplasm</b>	ukb-a-596	-0.1051	0.1798	0.624
<b>Celiac disease</b>	ebi-a-GCST000612	-0.111	0.06049	0.099
<b>Adiponectin</b>	ieu-a-1	-0.1113	0.09904	0.328
<b>Handedness (chirality/laterality): Left-handed</b>	ukb-a-36	-0.1159	0.05793	0.071
<b>Primary sclerosing cholangitis</b>	ieu-a-1112	-0.116	0.06281	0.097
<b>Underlying (primary) cause of death: ICD-10 E85.4 Organ limited amyloidosis</b>	ukb-a-357	-0.1165	0.1516	0.513
<b>Reason for glasses/contact lenses: For 'astigmatism'</b>	ukb-b-10937	-0.1169	0.05444	0.051
<b>Hippocampus volume</b>	ieu-a-1045	-0.1174	0.07937	0.194
<b>Circulating leptin levels adjusted for BMI</b>	ebi-a-GCST003368	-0.1182	0.06261	0.089
<b>Types of physical activity in the last 4 weeks: Heavy DIY</b>	ukb-b-13184	-0.1209	0.03288	0.0005
<b>ICD-10:H40 Glaucoma</b>	ukb-d-H40	-0.1261	0.09974	0.272
<b>Average weekly red wine intake</b>	ukb-b-5239	-0.1266	0.03039	8.55e-05
<b>Snoring</b>	ukb-b-17400	-0.1289	0.02703	6.01e-06
<b>Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Oral contraceptive pill or minipill</b>	ukb-b-9547	-0.1313	0.09084	0.204
<b>Target heart rate achieved</b>	ukb-b-16609	-0.1325	0.06173	0.051
<b>Time from waking to first cigarette</b>	ukb-b-2732	-0.1334	0.05758	0.034
<b>Average weekly champagne plus white wine intake</b>	ukb-b-5716	-0.1334	0.03629	0.0006
<b>Smoking cessation</b>	bbj-a-81	-0.1379	0.05149	0.013
<b>Apolipoprotein A-I</b>	ieu-b-107	-0.1414	0.02614	2.50e-07
<b>Father still alive</b>	ukb-b-13160	-0.1431	0.05824	0.024
<b>Breastfed as a baby</b>	ukb-b-13423	-0.1435	0.03765	0.0003
<b>Age at menarche</b>	ieu-a-1095	-0.1444	0.02859	1.58e-06
<b>Childhood intelligence</b>	ieu-a-16	-0.1468	0.06337	0.034
<b>Types of physical activity in the last 4 weeks: Other exercises</b>	ukb-b-8764	-0.1468	0.02738	3.20e-07
<b>Serum cystatin C (eGFRey)</b>	ieu-a-1106	-0.1475	0.06321	0.033
<b>Reason for glasses/contact lenses: For short-sightedness (called 'myopia')</b>	ukb-b-6353	-0.1485	0.03691	0.0001
<b>Frequency of stair climbing in the last 4 weeks</b>	ukb-b-298	-0.149	0.03157	7.49e-06
<b>Types of physical activity in the last 4 weeks: Light DIY</b>	ukb-b-11495	-0.1502	0.03017	2.19e-06
<b>Relative age voice broke</b>	ukb-b-5262	-0.1512	0.03396	2.55e-05
<b>Neo-openness to experience</b>	ieu-a-117	-0.1525	0.07922	0.083
<b>Diagnoses - main ICD-10: F31 Bipolar affective disorder</b>	ukb-a-525	-0.1526	0.09155	0.137

<b>Diagnoses - main ICD-10: S52 Fracture of forearm</b>	ukb-a-590	-0.1568	0.07432	0.056
<b>Mouth/teeth dental problems: None of the above</b>	ukb-b-17601	-0.1584	0.03055	7.99e-07
<b>Average weekly fortified wine intake</b>	ukb-b-1070	-0.1603	0.05517	0.007
<b>Types of transport used (excluding work): Public transport</b>	ukb-b-15957	-0.1625	0.03697	3.25e-05
<b>Lung cancer</b>	bbj-a-133	-0.1646	0.1237	0.247
<b>ECG, heart rate</b>	ukb-b-11361	-0.1655	0.0449	0.0005
<b>Age at menopause (last menstrual period)</b>	ukb-b-17422	-0.1659	0.02728	5.94e-09
<b>Fluid intelligence score</b>	ukb-b-5238	-0.166	0.02631	1.53e-09
<b>Sleep duration</b>	ukb-b-4424	-0.1675	0.02803	1.11e-08
<b>Types of physical activity in last 4 weeks: Walking for pleasure</b>	ukb-b-7337	-0.1689	0.03378	1.99e-06
<b>Types of physical activity in last 4 weeks: Strenuous sports</b>	ukb-b-7663	-0.1703	0.03473	3.13e-06
<b>Intelligence</b>	ebi-a-GCST006250	-0.1713	0.02216	8.32e-14
<b>Tinnitus, No, never</b>	ukb-d-4803_0	-0.1768	0.04258	9.05e-05
<b>Types of transport used (excluding work): Cycle</b>	ukb-b-17557	-0.1785	0.03327	3.18e-07
<b>HDL cholesterol</b>	ieu-b-109	-0.1824	0.02405	2.46e-13
<b>Alcohol usually taken with meals</b>	ukb-b-16878	-0.1868	0.02924	9.45e-10
<b>Impedance of leg (left)</b>	ukb-b-14068	-0.1874	0.02057	8.50e-19
<b>Qualifications: Other professional qualifications e.g., nursing, teaching</b>	ukb-b-13799	-0.1893	0.03094	4.77e-09
<b>Impedance of leg (right)</b>	ukb-b-7376	-0.1926	0.01997	6.12e-21
<b>Duration walking for pleasure</b>	ukb-b-703	-0.198	0.03999	2.49e-06
<b>Types of transport used (excluding work): Walk</b>	ukb-b-14926	-0.1986	0.03351	1.46e-08
<b>Past tobacco smoking</b>	ukb-b-2134	-0.2033	0.0239	1.639e-16
<b>Reason for glasses/contact lenses: Other eye condition</b>	ukb-b-15297	-0.209	0.1863	0.329
<b>Transport type for commuting to workplace: Walk</b>	ukb-b-15005	-0.2099	0.05665	0.0005
<b>Former vs current smoker</b>	ieu-a-963	-0.2132	0.06222	0.001
<b>Underlying (primary) cause of death: ICD-10 J84.1 Other interstitial pulmonary diseases with fibrosis</b>	ukb-a-358	-0.222	0.151	0.196
<b>Maximum workload during fitness test</b>	ukb-b-7551	-0.222	0.05436	0.0001
<b>Alcohol drinker status: Current</b>	ukb-d-20117_2	-0.2226	0.04012	1.21e-07
<b>Started insulin within one year diagnosis of diabetes</b>	ukb-b-8388	-0.2308	0.0789	0.007
<b>Transport type for commuting to workplace: Cycle</b>	ukb-b-15787	-0.2329	0.03618	6.97e-10
<b>Transport type for commuting to workplace: Public transport</b>	ukb-b-17155	-0.2347	0.03922	1.07e-08
<b>Smoking status: Never</b>	ukb-d-20116_0	-0.2386	0.02478	7.13e-21
<b>Qualifications: O levels/GCSEs or equivalent</b>	ukb-b-18099	-0.2447	0.02971	1.46e-15
<b>Vascular/heart problems diagnosed by doctor: None of the above</b>	ukb-b-13352	-0.2457	0.02317	4.30e-25
<b>Pulse wave peak to peak time</b>	ukb-b-8778	-0.2469	0.04531	2.05e-07
<b>Impedance of whole body</b>	ukb-b-19921	-0.2556	0.02064	7.70e-34
<b>Why reduced smoking: Health precaution</b>	ukb-b-13026	-0.2562	0.1216	0.056
<b>Age of smoking initiation</b>	ieu-b-24	-0.259	0.03105	6.37e-16
<b>Years of schooling</b>	ieu-a-1239	-0.2629	0.01929	1.39e-40
<b>College completion</b>	ieu-a-836	-0.2667	0.04041	2.45e-10
<b>Qualifications: College or University degree</b>	ukb-b-16489	-0.2679	0.02191	5.28e-33
<b>Mother's age at death</b>	ukb-b-12687	-0.2702	0.04147	4.25e-10
<b>Illness, injury, bereavement, stress in the last 2 years: None of the above</b>	ukb-b-17687	-0.2722	0.03142	4.36e-17
<b>Age completed full time education</b>	ukb-b-6134	-0.2722	0.02826	7.04e-21
<b>Maximum heart rate during fitness test</b>	ukb-b-14461	-0.2746	0.05061	2.33e-07
<b>Qualifications: A levels/ AS levels or equivalent</b>	ukb-b-11615	-0.2759	0.02525	1.35e-26
<b>Father's age at death</b>	ukb-b-11303	-0.2784	0.03921	8.12e-12
<b>Impedance of arm (right)</b>	ukb-b-7859	-0.2824	0.02113	3.82e-39
<b>Usual walking pace</b>	ukb-b-4711	-0.2833	0.02477	5.32e-29
<b>Impedance of arm (left)</b>	ukb-b-19379	-0.2844	0.02141	1.03e-38
<b>Parental longevity</b>	ebi-a-GCST006702	-0.2877	0.03995	4.02e-12
<b>Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: None of the above</b>	ukb-b-20379	-0.2901	0.03107	1.09e-19
<b>Duration of fitness test</b>	ukb-b-6011	-0.301	0.09015	0.002
<b>Age started oral contraceptive pill</b>	ukb-b-9433	-0.3324	0.03679	1.65e-18
<b>Age at first live birth</b>	ukb-b-12405	-0.3432	0.02573	5.27e-39
<b>Age at last live birth</b>	ukb-b-8727	-0.3554	0.03246	1.08e-26
<b>Medication for pain relief, constipation, heartburn: No medication</b>	ukb-b-11085	-0.4178	0.02462	2.02e-62
<b>Pain types experienced in last month: None of the above</b>	ukb-b-9130	-0.5107	0.02724	7.48e-76

**Table S10.** Exposures potentially causal for LSS, and outcomes that LSS was potentially found to be causal for. Mendelian randomization was performed by using TwoSampleMR-database and the phenotype IDs used in the analysis were extracted from the MRC-IEU database. For the analysis, we extracted genetic instruments from FinnGen+EstBB based meta-analysis results. Inverse variance weighted-model was used as a main method, but MR Egger was also utilised as a sensitivity analysis. P<0.05 was used as a threshold for statistical significance. nsnp, number of SNPs; OR, odds ratio, pFDR, false discovery rate-corrected p-value; pHET, p-value for heterogeneity; pPLE, p-value for pleiotropy

Direction	Trait	Method	nsnp	Causal estimate scale		pFDR	pHET	Egger intercept	pPLE
<b>Trait-&gt; SS</b>	Whole body fat-free mass    id:ukb-b-13354 Whole body fat-free mass    id:ukb-b-13354	IVW MR Egger	481 481	OR OR	1.78 (1.59–1.99) 1.53 (1.17–2.00)	2.22e-21 0.004	1.53e-46 2.53e-46	0.0023	0.2255
<b>Trait-&gt; SS</b>	Hip circumference    id:ukb-b-15590 Hip circumference    id:ukb-b-15590	IVW MR Egger	369 369	OR OR	1.51 (1.38–1.64) 1.60 (1.26–2.03)	2.62e-18 0.0004	1.05e-26 8.49e-27	-0.0012	0.6042
<b>Trait-&gt; SS</b>	Whole body fat mass    id:ukb-b-19393 Whole body fat mass    id:ukb-b-19393	IVW MR Egger	383 383	OR OR	1.48 (1.35–1.63) 1.66 (1.28–2.16)	2.82e-15 0.0004	3.46e-35 3.86e-35	-0.0022	0.3585
<b>Trait-&gt; SS</b>	Body mass index (BMI)    id:ukb-b-19953 Body mass index (BMI)    id:ukb-b-19953	IVW MR Egger	387 387	OR OR	1.55 (1.42–1.70) 1.60 (1.26–2.03)	2.22e-21 0.0004	8.53e-26 6.31e-26	-0.0006	0.7846
<b>SS-&gt; Trait</b>	Back pain    id:ukb-b-983 Back pain    id:ukb-b-983	IVW MR Egger	33 33	Beta Beta	0.02 (0.01–0.03) 0.03 (-0.02–0.07)	0.0001 0.581	2.46e-14 1.18e-14	-0.00017	0.9247

**Table S11.** Risk factors that were extracted from the GWAS database provided by the MRC Integrative Epidemiology Unit (IEU) (<https://gwas.mrcieu.ac.uk/>) and were used in the bi-directional mendelian randomization.

GWAS-ID	Year	Trait	Consortium	Sample size	Number of SNP's
<b>ieu-b-35</b>	2018	C-reactive protein level	NA	204402	2414379
<b>met-d-GlycA</b>	2020	Glycoprotein acetyls	NA	115078	12321875
<b>ukb-b-13354</b>	2018	Whole body fat-free mass	MRC-IEU	454850	9851867
<b>ukb-b-15590</b>	2018	Hip circumference	MRC-IEU	462117	9851867
<b>ukb-b-19393</b>	2018	Whole body fat mass	MRC-IEU	454137	9851867
<b>ukb-b-19953</b>	2018	Body mass index (BMI)	MRC-IEU	461460	9851867
<b>ukb-b-3957</b>	2018	Sleeplessness/insomnia	MRC-IEU	462341	9851867
<b>ukb-b-929</b>	2018	Frequency of tiredness/lethargy in last 2 weeks	MRC-IEU	449019	9851867
<b>ukb-b-9838</b>	2018	Back pain	MRC-IEU	461857	9851867

## References

1. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput Biol* **11**, e1004219 (2015).
2. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
3. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
4. Suri, P. *et al.* Genome-wide association studies of low back pain and lumbar spinal disorders using electronic health record data identify a locus associated with lumbar spinal stenosis. *Pain* **162**, 2263–2272 (2021).
5. Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank. *Nucleic Acids Res* **44**, D67–D72 (2016).
6. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* **47**, D506–D515 (2019).
7. Stanfill, A. G. & Cao, X. Enhancing Research Through the Use of the Genotype-Tissue Expression (GTEx) Database. *Biol Res Nurs* **23**, 533–540 (2021).
8. Cortes, A. *et al.* Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* **45**, 730–738 (2013).
9. Abe, Y. *et al.* Proinflammatory Cytokines Stimulate the Expression of Nerve Growth Factor by Human Intervertebral Disc Cells. *SPINE* vol. 32.
10. Freemont, A. J. *et al.* Nerve growth factor expression and innervation of the painful intervertebral disc. *Journal of Pathology* **197**, 286–292 (2002).
11. Hu, H. *et al.* OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. *Nature* **494**, 371–374 (2013).
12. Zhang, H., Liu, D. & Fan, X. Diagnostic and prognostic significance of miR-486-5p in patients who underwent minimally invasive surgery for lumbar spinal stenosis. *European Spine Journal* **33**, 1979–1985 (2024).
13. Russo, S. *et al.* A mutation in the ZNF687 gene that is responsible for the severe form of Paget's disease of bone causes severely altered bone remodeling and promotes hepatocellular carcinoma onset in a knock-in mouse model. *Bone Res* **11**, 16 (2023).
14. Divisato, G. *et al.* ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. *Am J Hum Genet* **98**, 275–86 (2016).
15. Varela, D., Varela, T., Conceição, N. & Cancela, M. L. Regulation of human ZNF687, a gene associated with Paget's disease of bone. *Int J Biochem Cell Biol* **154**, 106332 (2023).
16. Jacobsen, M. *et al.* A point mutation in PTPRC is associated with the development of multiple sclerosis. *Nat Genet* **26**, 495–499 (2000).
17. Dunlock, V.-M. E. *et al.* Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. *Cell Rep* **39**, 111006 (2022).
18. Luo, W., Zhang, G., Wang, Z., Wu, Y. & Xiong, Y. Ubiquitin-specific proteases: Vital regulatory molecules in bone and bone-related diseases. *Int Immunopharmacol* **118**, 110075 (2023).
19. Sun, C., Ma, Q., Yin, J., Zhang, H. & Liu, X. WISP-1 induced by mechanical stress contributes to fibrosis and hypertrophy of the ligamentum flavum through Hedgehog-Gli1 signaling. *Exp Mol Med* **53**, 1068–1079 (2021).
20. Qin, T. *et al.* Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. *J Exp Clin Cancer Res* **37**, 287 (2018).

21. Wright, K. M. *et al.* Dystroglycan organizes axon guidance cue localization and axonal pathfinding. *Neuron* **76**, 931–44 (2012).
22. Jahncke, J. N. & Wright, K. M. The many roles of dystroglycan in nervous system development and function. *Developmental Dynamics* **252**, 61–80 (2023).
23. Dai, Y. *et al.* Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. *J Cell Mol Med* **23**, 811–818 (2019).
24. Wang, F. M. *et al.* Aging of the Spine: Characterizing genetic and physiological determinants of spinal curvature. doi:10.1101/2024.02.27.24303450.
25. Veleri, S., Punnakkal, P., Dunbar, G. L. & Maiti, P. Molecular Insights into the Roles of Rab Proteins in Intracellular Dynamics and Neurodegenerative Diseases. *Neuromolecular Med* **20**, 18–36 (2018).
26. Jiang, J. *et al.* Involvement of Rab28 in NF-κB Nuclear Transport in Endothelial Cells. *PLoS One* **8**, (2013).
27. Prunier, C. & Howe, P. H. Disabled-2 (Dab2) Is Required for Transforming Growth Factor β-induced Epithelial to Mesenchymal Transition (EMT). *Journal of Biological Chemistry* **280**, 17540–17548 (2005).
28. Figliuolo da Paz, V., Ghishan, F. K. & Kiela, P. R. Emerging Roles of Disabled Homolog 2 (DAB2) in Immune Regulation. *Frontiers in Immunology* vol. 11 Preprint at <https://doi.org/10.3389/fimmu.2020.580302> (2020).
29. Wang, D. *et al.* Cyclic Mechanical Stretch Ameliorates the Degeneration of Nucleus Pulposus Cells through Promoting the ITGA2/PI3K/AKT Signaling Pathway. *Oxid Med Cell Longev* **2021**, 1–11 (2021).
30. Nechanitzky, R. *et al.* Transcription factor EBF1 is essential for the maintenance of B cell identity and prevention of alternative fates in committed cells. *Nat Immunol* **14**, 867–875 (2013).
31. Yang, C.-Y. *et al.* Interaction of CCR4-NOT with EBF1 regulates gene-specific transcription and mRNA stability in B lymphopoiesis. *Genes Dev* **30**, 2310–2324 (2016).
32. Kugimiya, F. *et al.* Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. *Journal of Biological Chemistry* **280**, 35704–35712 (2005).
33. Ebisawa, T. *et al.* Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. *J Cell Sci* **112** ( Pt 20), 3519–27 (1999).
34. Crews, L. *et al.* Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. *Journal of Neuroscience* **30**, 12252–12262 (2010).
35. Pulkkinen, H. H. *et al.* BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. *Angiogenesis* **24**, 129–144 (2021).
36. Hu, M.-M. & Shu, H.-B. Multifaceted roles of TRIM38 in innate immune and inflammatory responses. *Cell Mol Immunol* **14**, 331–338 (2017).
37. Hu, S., Li, Y., Wang, B. & Peng, K. TRIM38 protects chondrocytes from IL-1β-induced apoptosis and degeneration via negatively modulating nuclear factor (NF)-κB signaling. *Int Immunopharmacol* **99**, (2021).
38. Koike, Y. *et al.* Genetic insights into ossification of the posterior longitudinal ligament of the spine. *Elife* **12**, (2023).
39. Nakajima, M. *et al.* A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. *Nat Genet* **46**, 1012–1016 (2014).

40. Jokoji, G. *et al.* CDC5L promotes early chondrocyte differentiation and proliferation by modulating pre-mRNA splicing of SOX9, COL2A1, and WEE1. *Journal of Biological Chemistry* **297**, 100994 (2021).
41. Kim, S. K. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PLoS One* **13**, e0200785 (2018).
42. Kemp, J. P., Medina-Gomez, C., Tobias, J. H., Rivadeneira, F. & Evans, D. M. The case for genome-wide association studies of bone acquisition in paediatric and adolescent populations. *Bonekey Rep* **5**, 796 (2016).
43. Estrada, K. *et al.* Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**, 491–501 (2012).
44. Bian, Q. *et al.* Excessive Activation of TGF $\beta$  by Spinal Instability Causes Vertebral Endplate Sclerosis. *Sci Rep* **6**, 27093 (2016).
45. Hegewald, A. A. *et al.* Effects of initial boost with TGF-beta 1 and grade of intervertebral disc degeneration on 3D culture of human annulus fibrosus cells. *J Orthop Surg Res* **9**, 73 (2014).
46. Pham, D., Vincentz, J. W., Firulli, A. B. & Kaplan, M. H. Twist1 Regulates *Ifng* Expression in Th1 Cells by Interfering with Runx3 Function. *The Journal of Immunology* **189**, 832–840 (2012).
47. Salo, V. *et al.* Genome-wide meta-analysis conducted in three large biobanks expands the genetic landscape of lumbar disc herniations. doi:10.1101/2023.10.15.23296916.
48. Bjornsdottir, G. *et al.* Rare SLC13A1 variants associate with intervertebral disc disorder highlighting role of sulfate in disc pathology. *Nat Commun* **13**, 634 (2022).
49. Soranzo, N. *et al.* Meta-Analysis of Genome-Wide Scans for Human Adult Stature Identifies Novel Loci and Associations with Measures of Skeletal Frame Size. *PLoS Genet* **5**, e1000445 (2009).
50. Johansson, Å. *et al.* Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. *Hum Mol Genet* **18**, 373–380 (2009).
51. Nakamichi, R. & Asahara, H. The transcription factors regulating intervertebral disc development. *JOR Spine* **3**, (2020).
52. Nakamichi, R. *et al.* Mohawk promotes the maintenance and regeneration of the outer annulus fibrosus of intervertebral discs. *Nat Commun* **7**, 12503 (2016).
53. Shen, L. *et al.* miR-448 downregulates MPPE2 to promote cancer proliferation and inhibit apoptosis in oral squamous cell carcinoma. *Exp Ther Med* **12**, 2747–2752 (2016).
54. Schimunek, L. *et al.* MPPE2 Polymorphism Is Associated With Altered Systemic Inflammation and Adverse Trauma Outcomes. *Front Genet* **10**, (2019).
55. Liu, C. F. & Lefebvre, V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res* **43**, 8183–8203 (2015).
56. Lefebvre, V., Li, P. & de Crombrugghe, B. A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. *EMBO J* **17**, 5718–33 (1998).
57. Han, Y. & Lefebvre, V. L-Sox5 and Sox6 Drive Expression of the Aggrecan Gene in Cartilage by Securing Binding of Sox9 to a Far-Upstream Enhancer. *Mol Cell Biol* **28**, 4999–5013 (2008).
58. Nakajima, M., Koido, M., Guo, L., Terao, C. & Ikegawa, S. A novel CCDC91 isoform associated with ossification of the posterior longitudinal ligament of the spine works as

- a non-coding RNA to regulate osteogenic genes. *The American Journal of Human Genetics* **110**, 638–647 (2023).
- 59. Tan, Z. *et al.* Synergistic co-regulation and competition by a SOX9-GLI-FOXA phasic transcriptional network coordinate chondrocyte differentiation transitions. *PLoS Genet* **14**, e1007346 (2018).
  - 60. Inui, M. *et al.* USP15 is a deubiquitylating enzyme for receptor-activated SMADs. *Nat Cell Biol* **13**, 1368–1375 (2011).
  - 61. Meola, N. *et al.* Identification of a Nuclear Exosome Decay Pathway for Processed Transcripts. *Mol Cell* **64**, 520–533 (2016).
  - 62. Najmabadi, H. *et al.* Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **478**, 57–63 (2011).
  - 63. Revy, P., Kannengiesser, C. & Bertuch, A. A. Genetics of human telomere biology disorders. *Nat Rev Genet* **24**, 86–108 (2023).
  - 64. Itoh, Y. *et al.* A common SNP risk variant MT1-MMP causative for Dupuytren's disease has a specific defect in collagenolytic activity. *Matrix Biology* **97**, 20–39 (2021).
  - 65. Kosaka, H. *et al.* Pathomechanism of Loss of Elasticity and Hypertrophy of Lumbar Ligamentum Flavum in Elderly Patients With Lumbar Spinal Canal Stenosis. *Spine (Phila Pa 1976)* **32**, 2805–2811 (2007).
  - 66. Osthues, T. *et al.* The Lipid Receptor G2A (GPR132) Mediates Macrophage Migration in Nerve Injury-Induced Neuropathic Pain. *Cells* **9**, (2020).
  - 67. Styrkarsdottir, U. *et al.* Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31. *Nat Genet* **46**, 498–502 (2014).
  - 68. Chu, M. *et al.* The rs4238326 polymorphism in ALDH1A2 gene potentially associated with non-post traumatic knee osteoarthritis susceptibility: a two-stage population-based study. *Osteoarthritis Cartilage* **25**, 1062–1067 (2017).
  - 69. Zhu, L. *et al.* Variants in *ALDH1A2* reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis. *Sci Transl Med* **14**, (2022).
  - 70. Smith, T., Ferreira, L. R., Hebert, C., Norris, K. & Sauk, J. J. Hsp47 and cyclophilin B traverse the endoplasmic reticulum with procollagen into pre-Golgi intermediate vesicles. A role for Hsp47 and cyclophilin B in the export of procollagen from the endoplasmic reticulum. *J Biol Chem* **270**, 18323–8 (1995).
  - 71. van Dijk, F. S. *et al.* PPIB Mutations Cause Severe Osteogenesis Imperfecta. *The American Journal of Human Genetics* **85**, 521–527 (2009).
  - 72. Epstein, P. M., Basole, C. & Brocke, S. The Role of PDE8 in T Cell Recruitment and Function in Inflammation. *Front Cell Dev Biol* **9**, (2021).
  - 73. Wang, H. *et al.* Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. *Biochemistry* **47**, 12760–8 (2008).
  - 74. Allen, E. *et al.* Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. *Nature* **438**, 224–228 (2005).
  - 75. Martens, N. *et al.* Suppressor of Cytokine Signaling 7 Inhibits Prolactin, Growth Hormone, and Leptin Signaling by Interacting with STAT5 or STAT3 and Attenuating Their Nuclear Translocation. *Journal of Biological Chemistry* **280**, 13817–13823 (2005).
  - 76. Jho, E. *et al.* Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol Cell Biol* **22**, 1172–83 (2002).
  - 77. Houshyar, K. S. *et al.* Wnt Pathway in Bone Repair and Regeneration - What Do We Know So Far. *Front Cell Dev Biol* **6**, 170 (2018).

78. Li, X. *et al.* The adaptor protein Nck-1 couples the netrin-1 receptor DCC (deleted in colorectal cancer) to the activation of the small GTPase Racl through an atypical mechanism. *Journal of Biological Chemistry* **277**, 37788–37797 (2002).
79. Bu, G. *et al.* Increased expression of netrin-1 and its deleted in colorectal cancer receptor in human diseased lumbar intervertebral disc compared with autopsy control. *Spine (Phila Pa 1976)* **37**, 2074–2081 (2012).
80. Cousminer, D. L. *et al.* Genome-wide association study implicates novel loci and reveals candidate effector genes for longitudinal pediatric bone accrual. *Genome Biol* **22**, 1 (2021).
81. Zheng, Z. *et al.* CRLF1 Is a Key Regulator in the Ligamentum Flavum Hypertrophy. *Front Cell Dev Biol* **8**, (2020).
82. Xi, P., Ding, D., Zhou, J., Wang, M. & Cong, Y.-S. DDRGK1 regulates NF- $\kappa$ B activity by modulating I $\kappa$ B $\alpha$  stability. *PLoS One* **8**, e64231 (2013).
83. Egunsola, A. T. *et al.* Loss of DDRGK1 modulates SOX9 ubiquitination in spondyloepimetaphyseal dysplasia. *J Clin Invest* **127**, 1475–1484 (2017).
84. Raouf, A. & Seth, A. Ets transcription factors and targets in osteogenesis. *Oncogene* **19**, 6455–6463 (2000).
85. Malik, N. *et al.* Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. *Mol Cell Biol* **9**, 2847–53 (1989).
86. Sims, N. A. & Quinn, J. M. W. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. *Bonekey Rep* **3**, (2014).
87. Liu, T. *et al.* Chordin-Like 1 Improves Osteogenesis of Bone Marrow Mesenchymal Stem Cells Through Enhancing BMP4-SMAD Pathway. *Front Endocrinol (Lausanne)* **10**, (2019).
88. Gao, W.-L., Zhang, S.-Q., Zhang, H., Wan, B. & Yin, Z.-S. Chordin-like protein 1 promotes neuronal differentiation by inhibiting bone morphogenetic protein-4 in neural stem cells. *Mol Med Rep* **7**, 1143–8 (2013).
89. Kurakazu, I. *et al.* FOXO1 transcription factor regulates chondrogenic differentiation through transforming growth factor  $\beta$ 1 signaling. *Journal of Biological Chemistry* **294**, 17555–17569 (2019).
90. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**, 76–82 (2011).
91. Bakshi, A. *et al.* Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Sci Rep* **6**, (2016).
92. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
93. Martin, F. J. *et al.* Ensembl 2023. *Nucleic Acids Res* **51**, D933–D941 (2023).
94. Sliz, E. *et al.* Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata. *Nat Commun* **14**, 542 (2023).
95. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).